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ABSTRACT
Background. Cardiovascular disease (CVD) remains the most serious threat to life 
and health in industrialized countries. Atherosclerosis is the main underlying pathol-
ogy associated with CVD, in particular coronary artery disease (CAD), ischaemic 
stroke, and peripheral arterial disease. Risk factors play an important role in initiat-
ing and accelerating the complex process of atherosclerosis. Most studies of risk 
factors have focused on the presence or absence of clinically defi ned CVD. Less is 
known about the determinants of the severity and extent of atherosclerosis in symp-
tomatic patients.
Aims. To clarify the association between coronary and carotid artery atherosclero-
sis, and to study the determinants associated with these abnormalities with special 
regard to novel cardiovascular risk factors.
Subjects and methods. Quantitative coronary angiography (QCA) and B-mode 
ultrasound were used to assess coronary and carotid artery atherosclerosis in 108 
patients with clinically suspected CAD referred for elective coronary angiography. 
To evaluate anatomic severity and extent of CAD, several QCA parameters were 
incorporated into indexes. These measurements refl ected CAD severity, extent, and 
overall atheroma burden and were calculated for the entire coronary tree and sepa-
rately for different coronary segments (i.e., left main, proximal, mid, and distal seg-
ments). Maximum and mean intima-media thickness (IMT) values of carotid arter-
ies were measured and expressed as mean aggregate values. Furthermore, the study 
design included extensive fasting blood samples, oral glucose tolerance test, and an 
oral fat-load test to be performed in each participant.
Results. Maximum and mean IMT values were signifi cantly correlated with CAD 
severity, extent, and atheroma burden. There was heterogeneity in associations be-
tween IMT and CAD indexes according to anatomical location of CAD. Maximum 
and mean IMT values, respectively, were correlated with QCA indexes for mid and 
distal segments but not with the proximal segments of coronary vessels. The values 
of paraoxonase-1 (PON1) activity and concentration, respectively, were lower in 
subjects with signifi cant CAD and there was a signifi cant relationship between PON1 
activity and concentration and coronary atherosclerosis assessed by QCA. PON1 ac-
tivity was a signifi cant determinant of severity of CAD independently of HDL cho-
lesterol. Neither PON1 activity nor concentration was associated with carotid IMT. 
The concentration of triglycerides (TGs), triglyceride-rich lipoproteins (TRLs), oxi-
dized LDL (oxLDL), and the cholesterol content of remnant lipoprotein particle 
(RLP-C) were signifi cantly increased at 6 hours after intake of an oral fatty meal as 
compared with fasting values. The mean peak size of LDL remained unchanged 6 
hours after the test meal. The correlations between total TGs, TRLs, and RLP-C in 
fasting and postprandial state were highly signifi cant. RLP-C correlated with oxLDL 
A B S T R A C T
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both in fasting and in fed state and inversely with LDL size. In multivariate analysis 
oxLDL was a determinant of severity and extent of CAD. Neither total TGs, TRLs, 
oxLDL, nor LDL size were linked to carotid atherosclerosis. Insulin resistance (IR) 
was associated with an increased severity and extent of coronary atherosclerosis and 
seemed to be a stronger predictor of coronary atherosclerosis in the distal parts of 
the coronary tree than in the proximal and mid parts. In the multivariate analysis IR 
was a signifi cant predictor of the severity of CAD. IR did not correlate with carotid 
IMT. Maximum and mean carotid IMT were higher in patients with the apoE4 
phenotype compared with subjects with the apoE3 phenotype. Likewise, patients 
with the apoE4 phenotype had a more severe and extensive CAD than individuals 
with the apoE3 phenotype.
Conclusions. 1) There is an association between carotid IMT and the severity and 
extent of CAD. Carotid IMT seems to be a weaker predictor of coronary atheroscle-
rosis in the proximal parts of the coronary tree than in the mid and distal parts. 2) 
PON1 activity has an important role in the pathogenesis of coronary atherosclerosis. 
More importantly, the study illustrates how the protective role of HDL could be 
modulated by its components such that equivalent serum concentrations of HDL 
cholesterol may not equate with an equivalent, potential protective capacity. 3) RLP-
C in the fasting state is a good marker of postprandial TRLs. Circulating oxLDL 
increases in CAD patients postprandially. The highly signifi cant positive correlation 
between postprandial TRLs and postprandial oxLDL suggests that the postprandial 
state creates oxidative stress. Our fi ndings emphasize the fundamental role of LDL 
oxidation in the development of atherosclerosis even after inclusion of conventional 
CAD risk factors. 4) Disturbances in glucose metabolism are crucial in the patho-
genesis of coronary atherosclerosis. In fact, subjects with IR are comparable with 
diabetic subjects in terms of severity and extent of CAD. 5) ApoE polymorphism is 
involved in the susceptibility to both carotid and coronary atherosclerosis. 
A B S T R A C T
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1. INTRODUCTION
Atherosclerosis is a generalized disease of the arterial wall, which may progress or 
regress depending on a plethora of factors. The classic risk factors for atheroscle-
rosis in the general population are age, male gender, family history of premature 
cardiovascular disease (CVD), diabetes mellitus (DM), hypertension, smoking, high 
total and low-density lipoprotein (LDL) cholesterols, low high-density lipoprotein 
(HDL) cholesterol, and obesity (Fruchart et al. 2004). More recently, several novel 
risk factors, such as small, dense LDL, oxidized LDL (oxLDL), insulin resistance 
(IR), lipoprotein(a) [Lp(a)], apolipoprotein (apo)E4 isoform, HDL-bound paraox-
onase-1 (PON1), hypertriglyceridemia, and triglyceride-rich lipoproteins (TRLs) 
have been linked with an increased risk of CVD (Mackness et al. 2001, Carmena et 
al. 2004, Fruchart et al. 2004, Song et al. 2004). 
  Although risk factors play an important role, emerging evidence suggests that the 
impact of these on initiating and accelerating the complex process of atherosclerosis 
in different arterial territories is not similar (Faxon et al. 2004). Furthermore, most 
studies of cardiovascular risk factors have focused on the presence or absence of clini-
cally defi ned coronary artery disease (CAD). Less is known about the determinants 
of the severity and extent of coronary atherosclerosis in symptomatic patients. The 
severity and extent of CAD is important for prognosis, since people with no or mini-
mal narrowings have an excellent prognosis, whereas those with left main coronary 
disease or triple-vessel disease have an ominous clinical course without intervention. 
  Atherosclerosis often remains clinically “silent” for many years, and the fi rst clini-
cal manifestation of atherosclerotic disease is frequently a major cardiovascular event, 
such as myocardial infarction, stroke, or sudden death. Over recent decades the inter-
est in cardiovascular epidemiology has broadened from studies on causes and con-
sequences of elevated cardiovascular risk factors to include research on causes and 
consequences of atherosclerosis and associated arterial wall abnormalities. One of the 
underlying reasons was that established cardiovascular risk factors were insuffi ciently 
accurate in identifying those individuals who will suffer from CVD in future. 
  Because angiographic assessment of the coronary arteries is expensive and not 
without risk, ultrasonographic measurement of intima-media thickness (IMT) of 
easily accessible carotid arteries has been advocated as surrogate marker for coronary 
atherosclerosis. An increase in IMT of the carotid artery has been associated with 
established risk factors of CVD (Heiss et al. 1991, Salonen et al. 1991, Davis et al. 
2001), presence of CAD (Craven et al. 1990, Crouse et al. 1995), as well as the oc-
currence of cardiovascular events (Lorenz et al. 2007).
  Against this background the present study was undertaken to clarify, in a cohort 
of patients with clinically suspected CAD, the association between ultrasonically 
determined carotid atherosclerosis and anatomic distribution of coronary atheroma 
based on a computer-assisted analysis of coronary angiograms, and to study the 
determinants associated with these abnormalities with special regard to novel car-
diovascular risk factors. 
I N T R O D U C T I O N
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2. REVIEW OF THE LITERATURE
2.1. Pathogenesis of atherosclerotic vascular disease
Atherosclerosis is a pathological condition that underlies several important adverse 
vascular conditions including CAD, cerebrovascular disease, and peripheral arterial 
disease. The lesions of atherosclerosis occur principally in large and medium-sized 
arteries. The arterial wall consists of three anatomically distinct layers: the intima, 
media, and adventitia. The intima is separated from the media by the internal elastic 
lamina, which is considered to be part of the media. The external elastic lamina sepa-
rates the media from the adventitia (Stehbens 1995). Atherosclerosis is predomi-
nantly a disease of the intima and occurs at so-called lesion-prone sites near the ves-
sel branches and bifurcations at which local factors such as variable blood fl ow and 
low and oscillating shear infl uence the atherogenic process (Gotto et al. 1999).
  Traditionally, atherosclerotic changes in the arterial wall are divided into six char-
acteristic developmental stages (Figure 1). The earliest sign of atherosclerosis, the 
type I lesions, comprises formation of small isolated groups of macrophages fi lled 
with lipid droplets (foam cells). Type II lesions, grossly designated as fatty streaks, 
are characterized by closely packed lipid-laden macrophages, smooth muscle cells, 
and lymphocytes. By the time of puberty, a variable number of type I and type II 
lesions are present in nearly everyone to a variable extent. They may regress tempo-
rarily or permanently. The progression beyond the type II morphology requires an 
additional stimulus, i.e. risk factor for the development of atherosclerosis. Type III 
lesions, also known as preatheromas, form the bridge between early and advanced 
lesions. In addition to the features of type II lesions, type III lesions contain a mix-
ture of cell remnants and lipid droplets packed between smooth muscle cells of the 
deep (musculoelastic) layer of the intima, forming small separate pools in the spaces 
between the cells. Accumulation of this extracellular lipid constitutes the onset of 
progression beyond the earlier minimal changes. Lesion types I through III do not 
thicken the arterial wall appreciably and therefore do not narrow the lumen or ob-
struct blood fl ow (Stary et al. 1994). 
  By the end of the third decade of life, the fi rst potentially clinical lesions may be 
found at highly susceptible arterial locations; these are known as type IV lesions or 
atheroma. The cap of the lesion, i.e. the tissue layer between the lipid core and the 
endothelial surface, varies in thickness and contains macrophages, smooth muscle 
cells, and infl ammatory cells (Ross 1999). When the cap covering a lipid core under-
goes a substantial increase in fi brous tissue, the lesions are labeled type V. The nar-
rowing (loss) of the vascular lumen is a prominent feature of type V lesions. When 
lesions (generally types IV and V) include surface disruption, hematoma, thrombus 
or all of these together, they are called type VI or complicated lesions (Stary et al. 
1995). 
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  An atherosclerotic plaque, which is prone to rupture, is characterized by a large, 
lipid-rich atheromatous core and a thin fi brous cap. Moreover, the amount of in-
fl ammatory cells in the plaque is increased (Ross 1999, Hansson 2005, Falk 2006). 
In the event of erosion or rupture of atherosclerotic plaque, exposure of its throm-
bogenic content into the lumen of the artery activates platelets and the coagulation 
system leading to formation of a thrombus, which may partially or even totally oc-
clude the lumen of the coronary artery (Falk 2006). 
Figure 1. Evolution and progression of human atherosclerotic lesions. Modifi ed from 
Stary et al. (1995).
  CAD is largely not a disease of the lumen but an abnormality of the vessel wall. 
Regardless of the size of the lumen, if a plaque ruptures and a thrombus develops, 
a patient can experience an acute coronary syndrome or even sudden cardiac death. 
Thus, the traditional model (Figure 1) of the disease, in which the plaque devel-
ops in the vessel wall over many years, gradually narrowing the lumen to produce 
symptoms, is not completely correct. A more accurate model of atherosclerosis was 
originally described in a necropsy study by Glagov et al. (1987), who showed that, in 
the early course of atherosclerosis, coronary “remodeling” of the vessel wall enables 
patients to develop large atherosclerotic plaques without reduction in lumen size. 
According to Glagov et al. (1987), lumen reduction does not occur until the plaque 
occupies >40% of the total vessel cross-sectional area. More recently, this phenom-
enon of “arterial remodeling” has been confi rmed in vivo by the use of intracoronary 
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ultrasound imaging (De Franco et al. 2001). Positive remodeling is defi ned as a com-
pensatory outward expansion of local vessel size in response to plaque accumulation. 
Negative remodeling is described as the shrinkage of local vessel size in association 
with the development of CAD (De Franco et al. 2001). Intracoronary ultrasound 
studies have demonstrated an association between the direction of remodeling and 
clinical presentation. Acute coronary syndromes are more commonly characterized by 
positive than negative remodeling, whereas lesions accompanied by negative remod-
eling are associated with stable angina pectoris (Schoenhagen et al. 2001). Further, 
remodeling has been shown to occur much less in distal coronary artery segments 
than in proximal segments (Burke et al. 2002).
  The pathophysiology of vascular remodeling is not fully understood. However, 
available data suggest that remodeling is initiated by changes in hemodynamic con-
ditions (fl ow, wall stretch, shear stress) and humoral factors (cytokines, vasoactive 
substances) (Schoenhagen et al. 2001). Histopathologic studies have revealed that 
plaque components, such as macrophage burden, lipid core size, calcium (in fi brous 
plaque and lipid core), and medial atrophy are strongly asscoiated with positive re-
modeling, whereas fi brous areas are negatively correlated with remodeling.
2.2. A short overview of lipoprotein metabolism
2.2.1. The major lipoprotein species
The major fatty substances or lipids in the plasma are fatty acids, triglycerides (TGs), 
cholesterol (free and esterifi ed cholesterol), and phospholipids. They are important 
in maintaining the structure of the cell membrane (cholesterol, phospholipids), and 
as substrates for steroid hormone synthesis (cholesterol) and energy metabolism 
(TGs, fatty acids). Since lipids are insoluble in the aqueous milieu of blood plasma, 
they have to be packaged into particles known as lipoproteins (Gotto et al. 1986). 
Lipoproteins consist of a hydrophobic core of cholesteryl esters and TGs surrounded 
by a hydrophilic surface of free (unesterifi ed) cholesterol, phospholipids, and apoli-
poproteins.
  Apolipoproteins maintain the structural integrity of lipoproteins and direct their 
metabolic interactions with cell-surface receptors, hydrolytic enzymes, and lipid 
transport proteins. As outlined in Table 1, plasma lipoproteins are traditionally clas-
sifi ed, according to the density at which they fl oat during ultracentrifugation, into 
fi ve categories: chylomicrons (CMs), very low-density lipoproteins (VLDLs), inter-
mediate-density lipoproteins (IDLs), LDLs, and HDLs. Some lipoprotein subclasses 
can be further separated by particle size, electrophoretic mobility, and apolipopro-
tein content.  
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Table 1. Physiochemical properties, lipid and apolipoprotein composition of the 




CM VLDL IDL LDL HDL
Density range 
(g/mL)
<0.96 0.96-1.006 1.006-1.019 1.019-1.063 1.063-1.210
Particle size
(diameter, nm)
75-1200 30-80 25-35 18-25 5-12
Flotation rate (Sf)* 400-10,000 20-400 12-20 0-12
Composition (%)
TG 86 55 23 6 5
PL 7 18 19 22 33
CE 4 12 29 42 17
FC 2 7 9 8 5












Source Intestine Liver Lipolysis of 
VLDL
Lipolysis of 





CM, chylomicron; VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; PL, phospholipid; CE, cholesteryl 
ester; FC, free cholesterol
*Svedberg fl otation rate at 26ºC and d 1.063 g/ml (not applicable to HDL).
†There are three apoC peptides: apoC-I, apoC-II, and apoC-III.
Adapted from Gotto et al. (1986) and Ginsberg (1990).
2.2.2. Triglyceride-rich lipoprotein
2.2.2.1. Defi nition and characteristics of chylomicrons
Dietary fat is digested in the small intestine and absorbed into the enterocytes. Within 
the enterocytes, the exogenous free fatty acids, glycerols, and monoacylglycerols are 
packaged as TGs together with cholesteryl esters, phospholipids, and proteins into 
CM particles (Green et al. 1981, Bisgaier et al. 1983). 
  CMs are secreted into the intestinal lymph and transported into the bloodstream 
via the thoracic duct. The secreted CMs interact with HDLs, donating apoA-I, 
apoA-II, apoA-IV, and phospholipids and receiving apoCI, apoCII, apoCIII, and 
apoE (Gotto et al. 1986). ApoB-48, a specifi c apolipoprotein constituent of CMs, 
remains within the CM particle throughout its life span. Lipoprotein lipase removes 
TGs from the CM particles to be utilized in peripheral tissues. Thereafter, CMs be-
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come remnant particles, which are taken up by the hepatic cells. The cellular uptake 
of CM remnants is mediated by multiple interactions of apoE and lipoprotein lipase 
with heparan sulfate proteoglycans, the LDL receptor, and the LDL receptor-re-
lated protein (Beisiegel et al. 1991, Heeren et al. 2001) (Figure 2).
Figure 2. Schematic illustration of lipoprotein metabolism. For explanation, see text 
(chapter 2.2.2.). A-I, A-II, A-IV, B-48, B-100, E, apolipoproteins; Cs, apolipoproteins 
C-I, C-II, C-III; CM, chylomicron; HDL, high-density lipoprotein; IDL, intermediate-
density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; 
LDL-R, LDL receptor; LRP, LDL receptor-related protein; LPL, lipoprotein lipase; 
HL, hepatic lipase; TG, triglyceride; PL, phospholipid; CE, cholesteryl ester; PLTP, 
phospholipid transfer protein; CETP, cholesteryl ester transfer protein. 
Modifi ed and used with permission from Kati Ylitalo, Doctoral Thesis 2001.
2.2.2.2. Defi ntion and characteristics of very low-density 
lipoproteins 
VLDLs are secreted from the liver and contain cholesterol, TGs, apoB-100, apoE, 
and apoCs. The apoE and some of the apoCs are transferred from HDL to VLDL. 
ApoB-100, synthesized in the liver, is the main apolipoprotein of VLDL. Likewise 
the catabolic pathways of CMs, VLDLs are hydrolyzed by lipoprotein lipase to 
VLDL remnants. As a result of TG depletion, VLDL remnants can be removed 
directly by the liver or converted into IDL particles. IDLs are further hydrolyzed by 
hepatic lipase and lipoprotein lipase into LDL (Demant et al. 1988) (Figure 2).
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  By defi nition, the term remnant refers to an apoB-containing lipoprotein that 
has delivered some, or major parts, of its original TG content to peripheral tissues 
by means of lipoprotein lipase-mediated lipolysis (Karpe 1999). In a sense, all apoB-
containing lipoproteins are remnants because the intestinally derived CMs and liver-
derived VLDLs are nascent particles that are rapidly catabolized. It has been shown 
that the half-life of the removal of intravenously injected CMs from circulation varies 
from 5 to 13 minutes (Nestel 1964). 
  Taken together, TRLs are highly heterogeneous in size, density, and compo-
sition. They comprise intestinally derived apoB-48 containing CMs, liver-derived 
apoB-100 containing VLDLs, and their remnants (Havel 1994). The capacity of 
TRLs to enter the arterial intima is inversely related to the size of the lipid particle. 
Whereas CMs and large VLDLs (Svedberg fl otation unit [Sf] 60-100) are unable to 
pass through the endothelial layer, smaller VLDLs (Sf 20-60) and IDLs (Sf 12-20) 
can enter the subintimal space (Nordestgaard 1996). 
2.2.3. Low-density lipoprotein 
2.2.3.1. Structure of the LDL particle
LDL is a spherical particle composed of a central core of cholesteryl esters and TGs. 
It is surrounded by a polar coat comprising unesterifi ed cholesterol, phospholipids, 
and an essential structural protein called apoB-100. Each LDL particle has one apoB 
molecule. ApoB-100 binds to the LDL receptor and is therefore a crucial link in the 
normal pathway by which LDL is removed from plasma.
  About half of the fatty acids in LDL are polyunsaturated fatty acids, mainly li-
noleic acid with minor amounts of arachidonic and docosahexaenoic acid. These 
polyunsaturated fatty acids are protected against free radical attack and oxidation 
by antioxidants, primarly α-tocopherol (~ six molecules per LDL particle), with 
minor amounts of γ-tocopherol, carotenoids, cryptoxanthin, and ubiquinol-10. The 
amount of polyunsaturated fatty acids and antioxidants varies signifi cantly within 
individuals, resulting in a great variation in LDL oxidation susceptibility (Mertens 
et al. 2001). 
2.2.3.2. LDL metabolism 
Most LDL particles originate from the metabolism of TRLs. In this VLDL-IDL-
LDL cascade, the particle is depleted of TGs and loses most of the associated apoli-
poproteins, except for apoB-100. A small amount of LDL can also be synthesized 
directly by the liver. LDLs are removed from the plasma mainly via receptor-me-
diated endocytosis by LDL receptors on the surface of liver cells. The number of 
LDL receptors expressed by liver cells is controlled by negative-feedback regula-
tion. When the concentration of cholesterol in hepatocytes rises, transcription of 
the LDL receptor gene is suppressed, and LDL is retained in plasma. In contrast, 
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when hepatic cholesterol level falls, LDL receptor gene transcription is induced, 
LDL is taken up more rapidly, and the amount of LDL in plasma falls (Brown et al. 
1986). 
2.2.3.3. LDL subfractions 
LDLs are a heterogenous class of particles that can be fractionated into subclasses by 
analytical ultracentrifugation (Lindgren et al. 1969), density gradient ultracentrifu-
gation (Krauss et al. 1992), gradient gel electrophoresis (Krauss et al. 1992), nuclear 
magnetic resonance (Otvos et al. 1992), or size exclusion chromatography (Marais 
2000). Analytical ultracentrifugation, the original gold standard, measures the fl ota-
tion velocity of LDL in a gravitational fi eld; the faster the velocity, the more lipid rich 
the LDL. This method is currently available only in a few research laboratories world-
wide. The simpler and less labor intensive density gradient ultracentrifugation sepa-
rates LDL into three fractions: large, buoyant LDL (1.025<d<1.034 g/mL), inter-
mediate size LDL (1.034<d<1.044 g/mL), and small, dense LDL (1.044<d<1.060 
g/mL) (Griffi n et al. 1990). The commonly used gradient gel electrophoresis yields 
two different LDL subclasses: pattern A and pattern B. In pattern A, the major peak 
of LDL particle diameter is greater than 25.5 nm. In pattern B, the major peak of 
LDL particle diameter is less or equal to 25.5 nm (Austin et al. 1988). Gradient gel 
electrophoresis has been extensively validated using ultracentrifugation. Unlike ultra-
centrifugation, gradient gel electrophoresis does not quantify the concentration of a 
particular species of LDL. Nuclear magnetic resonance is the most convenient and 
rapid method for measuring LDL size and concentration. However, validation stud-
ies using nuclear magnetic resonance and ultracentrifugation on the same samples in 
large populations have not been published (Sacks et al. 2003). 
2.2.4. High-density lipoprotein 
2.2.4.1. Structure of the HDL particle
HDLs are the smallest and densest of the major lipoprotein classes. They consist of 
a hydrophobic core surrounded by a surface of phospholipids, free cholesterol, and 
apolipoproteins. ApoA-I and apoA-II are the main structural proteins in HDL, ac-
counting for approximately 70% and 20%, respectively, of total HDL protein mass. 
As a result, plasma apoA-I concentrations correlate closely with those of plasma 
HDL cholesterol. ApoA-IV, apoA-V, apoC-I, apoC-II, apoC-III, apoD, apoE, and 
apoJ are found in lower amounts in mature HDLs. Some HDL-associated proteins 
are enzymatically active, e.g. lecithin:cholesterol acyltransferase (LCAT), PON1, 
platelet activating factor-acetylhydrolase, and glutathione peroxidase, or provide a 
transport vehicle for other plasma proteins that are involved in lipid metabolism, 
including cholesteryl ester- and phospolipid transfer proteins (CETP, PLTP) (Barter 
et al. 2003) (Figure 3). 
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2.2.4.2. HDL subfractions and apolipoproteins
The HDL fraction in human plasma is heterogeneous in terms of shape, size, den-
sity, protein composition, and surface charge. When isolated on basis of density by 
ultracentrifugation, the major subpopulations of HDLs are HDL2 (1.063<d<1.125 
g/mL) and HDL3 (1.125<d<1.210 g/mL) (Havel et al. 1955). According to par-
ticle sizes, HDL can be divided into HDL2b (12.9-9.7 nm), HDL2a (9.7-8.8 nm), 
HDL3a (8.8-8.2 nm), HDL3b (8.2-7.8 nm), and HDL3c (7.8-7.2 nm) in non-dena-
turating polyacrylamide gradient gel electrophoresis (Nichols et al.1986). By im-
munoaffi nity chromatography HDL can also be classifi ed on the basis of its main 
apolipoproteins to particles containing only apoA-I (LpA-I) and those containing 
both apoA-I and apoA-II (LpA-I/A-II). Most of the LpA-I is found in HDL2 
density range, while LpA-I/A-II predominates in HDL3 density range (Cheung et 
al.1982). In addition, HDL can be distinguished into pre-α-HDL, α-HDL, and 
pre-β-HDL according to the particle surface charge (Davidson et al. 1994). 
2.2.4.3. Metabolism of HDL particles 
ApoA-I is secreted predominantly by the liver and small intestine as lipid-poor 
apoA-I and nascent discoidal, phospholipid-rich, cholesterol-poor HDL particles. 
The nascent HDL is also formed during lipolysis of TRLs, namely CMs and VLDLs 
(Eisenberg 1984). ApoA-II is produced in the liver only. The nascent lipid-poor 
apoA-I-phospholipid complexes are termed as pre-β-HDL particles due to their 
electrophoretic motility (Davidson et al. 1994). ATP-binding cassette transporter 
A1 (ABCA1) is an important cellular protein that facilitates effl ux of cellular choles-
Figure 3. Structure of the HDL parti-
cle. For explanation, see text (chapter 
2.2.4.). PL, phospholipid; FC, free 
cholesterol; CE, cholesterol ester; TG, 
triglyceride; ApoA-I, apolipoprotein 
A-I; ApoA-II, apolipoprotein A-II; 
PAF-AH, platelet activating factor-
acetylhydrolase; PON-1, paraoxonase-
1; GPX, glutathione peroxidase.
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terol to the pre-β-HDL particles (Lawn et al. 1999). LCAT esterifi es the cholesterol 
on the nascent HDL, transforming the discoid particles into mature, lipid-rich, 
and spherical HDL containing a core of cholesteryl esters and two molecules of 
apoA-I (Rye et al. 1999). The apolipoproteins in HDL, including apoA-I, apoA-II, 
apoA-IV, and apoC-I, activate the esterifi cation of LCAT. PLTP, in turn, transfers 
the surface lipids from the post-lipolytic VLDL and CM particles to HDL (Tall 
1995). The net effect of CETP action on HDL is depletion of cholesteryl esters 
and enrichment with TGs. Hepatic lipase converts TG-enriched HDL to smaller 
HDL remnants, pre-β-HDL and lipid-poor or free apoA-I (Clay et al. 1992). The 
endothelial lipase hydrolyses HDL phospholipids generating free fatty acids, which 
are taken up by the endothelial cells. 
  Lipids or proteins of mature HDL are removed from the circulation by at least 
two direct pathways, which involve the selective uptake of lipids by hepatic scavenger 
receptor class B type 1 and the holoparticle uptake by apoE or apoA-I receptors, 
respectively, and two indirect pathways, which involve the action of CETP and he-
patic and endothelial lipases. The removal of lipids regenerates lipid-poor or lipid-free 
apoA-I, which can leave the plasma into the extravascular space. There they serve as 
acceptors of cellular lipids and thus again initiate the generation of HDL. In the kid-
ney, these small particles are fi ltered and removed from the plasma (von Eckardstein 
et al. 2001) (Figure 4).
Figure 4. Pathways involved in the generation and conversion of HDL. For explanation, 
see text (chapter 2.2.4.). Blue arrows represent lipid transfer processes, and red arrows 
represent protein transfer processes.  Abbreviations as in Figure 2. 
Modifi ed and used with permission from von Eckardstein et al. (2001) and the publisher 
(LWW).
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2.3. Risk factors for atherosclerotic vascular disease
2.3.1. Defi nition of risk factor
Risk factors play an important role in initiating and accelerating the complex process 
of atherosclerosis. From an epidemiological perspective, a “risk factor” is a charac-
teristic, a condition, or behavior of an individual or population that is associated with 
an increased risk for development of future disease. The defi nition is broad and does 
not necessarily imply a causal relationship. For a risk factor to be considered causal, 
the marker of interest must predate the onset of disease and must have biological 
plausibility. Therefore, much effort has been devoted to ascertaining whether vari-
ous risk factors, particularly those that can be modifi ed, are true causes of CVD.
  Absolute risk refers to the probability of developing a condition (e.g., CAD) 
over a specifi c time period. Relative risk is the ratio of the absolute risk of a given 
patient (or group) to that of a low-risk group. The term relative risk represents the 
ratio of the incidence in the exposed population divided by the incidence in unex-
posed persons. In a sense, relative risk refl ects the rate at which a person is accruing 
absolute risk (Grundy et al. 1998). Single risk factors, such as blood pressure or 
serum cholesterol are very poor predictors of absolute risk. Counting the number of 
risk factors present improves accuracy, but the most accurate method of absolute risk 
estimation is to count and weight appropriately all the major risk factors for CVD 
(Grover et al. 1995). This is done using risk equations, which are derived from large 
epidemiological studies. 
2.3.2. Traditional risk factors
The Framingham Heart Study, initiated in 1948 in the predominantly Caucasoid 
general population of Framingham, Massachusetts, has contributed importantly to 
our understanding of the causes of coronary heart disease (CHD). The major and 
independent risk factors or the so-called traditional, established, or conventional 
cardiovascular risk factors, studied extensively and incorporated in the Framingham 
risk chart, are advancing age, gender, cigarette smoking, hypertension, elevated to-
tal and LDL cholesterols, low levels of HDL cholesterol, and DM. Family history 
has been omitted because its independent effect on CHD risk is less (Grundy et al. 
1998). The Framingham risk chart provides an estimate of relative and absolute risk 
of developing CHD over a 10-year period. 
  Several problems have been noted with the Framingham risk chart, however. 
First, it was derived from American data, and the applicability of the risk chart to 
European population is uncertain. Second, the data set used for the chart was fairly 
small. Thirdly, the defi ntion of non-fatal end-points differed from those used in 
many other cohort studies, making it diffi cult to validate the chart (Conroy et al. 
2003). Accordingly, a new model for total risk estimation based on the SCORE 
(Systematic Coronary Risk Evaluation) system has been launched. The SCORE risk 
assessment system is obtained from a large dataset of prospective European studies, 
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using fi ve categorical variables, looking at northern and southern European coun-
tries, and measuring as the end point the absolute risk of cardiovascular mortal-
ity in the next 10 years. European guidelines recommend the SCORE as the new 
model for cardiovascular risk estimation (De Backer et al. 2003). Taken together, 
risk charts have been considered helpful in tailoring a plan for risk management in 
clinical practice. 
2.3.2.1. Age
Although not subject to modifi cation, age is among the most important risk factors 
for predicting incident CVD. The absolute risk for CVD increases with age in both 
men and women (Kannel et al. 1978, Schildkraut et al. 1989). In a 14-point scoring 
system, derived from the Framingham Heart Study, up to seven points can be attrib-
uted to age alone. Moreover, the risk of ischemic stroke doubles in each successive 
decade after 55 years of age (Wolf et al.1992). Thus, age is an overriding risk factor 
for incident CVD. It is acknowledged, however, that age is mainly a surrogate for 
an individual´s atherosclerotic burden, but a highly imprecise one (Grundy 1999). 
Replacement of age in risk assessment with a more precise marker – such as a non-
invasive image modality – might improve predictive accuracy, but this hypothesis has 
not, as yet, been adequately tested. 
  At an individual level there is a wide variation in both the occurrence of CHD 
and the time of manifestation, even in individuals with much the same risk profi les. 
Therefore, the hypothesis has emerged that, at least to some extent, interindivid-
ual differences in biological ageing could affect susceptibility to CHD. Eukaryotic 
chromosomes end with telomeres, which progressively shorten with cellular age-
ing. Shorter telomeres indicate increased biological age. Interestingly, Brouilette 
et al. (2007) concluded, in a prospective randomised primary prevention trial of a 
statin, that individuals with shorter leucocyte telomere length at the time of recruit-
ment had a signifi cantly higher risk of developing subsequent CHD. Of note, this 
increased risk with shorter baseline telomeres was attenuated in subjects receiving 
treatment with a statin.
2.3.2.2. Gender
Epidemiological studies, including the Framingham Heart Study, have demonstrated 
that men exhibit excess risk for CVD compared with women, particularly premeno-
pausal women (Kannel et al. 1995). This applies, however, only to the non-diabetic 
population, since DM largely blunts the benefi t of female sex. The reasons for this 
gender difference in the impact of type 2 DM on CHD risk remain incompletely 
understood, but could be related at least in part to a heavier risk factor burden, a 
greater effect of blood pressure, and atherogenic dyslipidemia in diabetic women 
(Juutilainen et al. 2004).
  The incidence of CHD in women lags behind that in men by 10 to 15 years, 
but the onset of menopause quadruples the risk of coronary events (Kannel et al. 
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1995). Some of this apparent protection could be due to the fact that premenopau-
sal women exhibit relatively lower concentrations of total cholesterol, LDL choles-
terol, and TGs and higher concentrations of HDL cholesterol than age-matched 
men (Williams 1997). Moreover, cigarette smoking has been substantially less fre-
quent in the past in women compared to men, but trends appear to be reversing in 
young women (Collins 2006).
  An impressive body of evidence from epidemiological studies has indicated a 
powerful protective effect of hormone-replacement therapy on the risk and develop-
ment of CHD in postmenopausal women (Collins 2006). However, the results from 
both primary (Writing Group for the Women´s Health Initiative [WHI] investiga-
tors 2002) and secondary prevention trials (Hulley et al. 1998) have failed to show 
any benefi t of hormone-replacement therapy on CHD risk. These divergent fi ndings 
were suprising, especially in view of the positive impact of estrogen therapy on circu-
lating LDL, HDL, and Lp(a) concentrations (Humphrey et al. 2002). The failure of 
the clinical trials to demonstrate a reduction in CHD events may be, in part, due to 
the selection of the population in terms of age and to the dose and possibly the type 
of steroids being employed. Notably, hormone-replacement therapy has also been 
associated with potentially unfavorable effects, including increased levels of TGs, 
factor VII, C-reactive protein, and decreased levels of antithrombin III (Humphrey 
et al. 2002).
2.3.2.3. Smoking
Cigarette smoking has long been recognized as a risk factor for CVD. Framingham 
data reveal that smoking is a powerful risk factor for myocardial infarction, even 
stronger than for angina pectoris (Hubert et al. 1982) and smokers have a 1.8-fold 
increase in stroke risk (Wolf et al. 1991).
  The pathophysiological effects of smoking are multifactorial. Smoking causes 
reduced blood vessel distensibility and compliance, thus leading to increased wall 
stiffness (Kool et al. 1993). Moreover, smoking is associated with increased fi brino-
gen levels, increased platelet aggregation, decreased HDL cholesterol levels, and 
increased hematocrit (Cruickshank et al. 1989). Taken together, smoking probably 
destabilizes plaques and promotes plaque rupture and thrombosis.
  The risk of future CVD is particularly high if smoking starts before the age of 15 
years (Kawachi et al. 1993). Moreover, the adverse effect of smoking is related to the 
amount of tobacco smoked daily and to the duration of smoking (Teo et al. 2006). 
On the other hand, smoking cessation rapidly and markedly reduces the risk for my-
ocardial infarction. A large part of the excess risk of myocardial infarction associated 
with smoking dissipates within fi ve years, and among light smokers (<10 cigarettes 
per day) there is no excess risk 3-5 years after quitting. However, the excess risk does 
not seem to have completely disappeared even 20 years after quitting in those who 
are heavy smokers (≥20 cigarettes per day) (Teo et al. 2006).
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2.3.2.4. Hypertension
The importance of elevated blood pressure, both systolic and diastolic, as a risk 
factor for CVD in both men and women has been demonstrated in a large number 
of epidemiological studies (Assmann et al. 1988, MacMahon et al. 1990, Kannel 
1996). The approximately linear relation between blood pressure and the incidence 
of CVD is supported by numerous studies demonstrating that antihypertensive ther-
apy does in fact decrease the risk for both heart attack and stroke (Moser et al. 1991, 
Cutler et al. 1995). However, the blood pressure elevation as well as its treatment 
is more obviously related to the incidence of stroke than to the incidence of CAD 
(MacMahon et al. 1990, Collins et al. 1992). It has also been documented that, 
compared with normotensive individuals, those with an elevated blood pressure 
more commonly have other risk factors (dyslipidemia, IR, DM) for CVD (Assmann 
et al. 1988, Isomaa et al. 2001).
2.3.2.5. Total cholesterol and LDL cholesterol
There is a strong and graded positive association between total as well as LDL cho-
lesterol and the risk of CVD. The association applies to individuals with asympto-
matic CVD as well as to patients with established disease (Neaton et al. 1992, Smith 
et al. 1992, Pedersen et al. 1998, Simes et al. 2002), to women as well as men, and 
to old as well as younger people (Clarke et al. 2002).
  A recent prospective meta-analysis of data from 90 056 individuals in 14 ran-
domised primary and secondary prevention trials showed that statin therapy can safely 
reduce the 5-year incidence of major coronary events, coronary revascularisation, and 
stroke by about one fi fth per mmol/L reduction in LDL cholesterol, largely irrespec-
tive of the initial lipid profi le (Cholesterol Treatment Trialists´ Collaborators 2005).
2.3.2.6. HDL cholesterol
One of the main CAD risk factors, discovered already in the early 1950s, is low HDL 
cholesterol (Nikkilä 1953). Thereafter, large prospective studies such as the Tromsø 
Heart-Study (Miller et al. 1977) and the Framingham Heart Study (Gordon et al. 
1977, Abbott et al. 1988, Wilson et al. 1988) have confi rmed the inverse association 
between HDL cholesterol levels and CAD. The estimated reduction of CAD risk by 
each 0.026 mmol/L (1 mg/dL) increase in HDL cholesterol is 2% in men and 3% 
in women (Gordon et al. 1989). The Copenhagen City Heart Study found a 47% 
reduction of ischemic stroke events for every 1-mmol/L increase in HDL choles-
terol (Lindenstrom et al. 1994).
  Despite a strong epidemiological association, the mechanism by which HDL 
exerts its benefi cial effects on CHD is still debated. Traditionally, the main hypoth-
esis for the anti-atherogenic function of HDL has been that of reverse cholesterol 
transport (Stein et al. 1999). Evidence that cholesterol effl ux is indeed crucial has 
been provided in mice demonstrating that a selective expression of ABCA1 in mac-
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rophages is anti-atherogenic, even though plasma lipoprotein levels remain un-
changed (Aiello et al. 2002). Moreover, Attie et al. (2001) found, in heterozygotes 
for mutation in the ABCA1 gene, lower levels of apoA-I and HDL together with 
an increase of carotid IMT. Several alternative or concomitant hypotheses empha-
sizing the anti-atherogenic role of HDL have been presented including inhibition 
of LDL oxidation by HDL-bound PON1 (Mackness et al. 1993), protection of 
endothelial cells from cytotoxic damage caused by remnants of TRLs (Chung et al. 
1989), regulation of coagulation and fi brinolysis and inhibition of platelet function 
(Nofer et al. 2002), stimulation of endothelial nitric oxide production (Yuhanna 
et al. 2001), and inhibition of the chemotaxis of monocytes and the adhesion of 
leukocytes to the endothelium (Nofer et al. 2002). 
2.3.2.7. Diabetes mellitus
CAD causes much of the serious morbidity and mortality in patients with DM. This 
pertains to the more prevalent type 2 DM but also to type 1 DM of long duration, 
especially after the development of nephropathy. Diabetic patients have a 3- to 5-fold 
increase in the risk of CAD (Kannel et al. 1979, Pyörälä et al. 1987). Patients with 
medically treated DM but without previous myocardial infarction carry the same level 
of subsequent coronary events as non-diabetic patients with previous myocardial in-
farction (Haffner et al. 1998). Although in other populations pre-existing CAD has 
been a stronger risk factor for future CAD events than DM (Lotufo et al. 2001, Hu 
et al. 2001), the greatly increased risk conferred by DM is undisputable. In addi-
tion, the case-fatality rates of myocardial infarction are greater in diabetic compared 
with non-diabetic patients (Miettinen et al. 1998). These observations have led the 
Adult Treatment Panel III (ATPIII) of the National Cholesterol Education Program 
(NCEP) to establish type 2 DM as a CHD equivalent (Expert panel 2002). Further, 
individuals with DM have a 1.5- to 4-fold increase in the risk of ischemic stroke 
(Beckman et al. 2002).
  Increasing evidence suggests that DM alters function of multiple cell types. 
Firstly, hyperglycemia impairs endothelium-dependent vasodilation by reducing am-
bient concentrations of nitric oxide. Concomitantly, vasoconstriction is augmented 
by increased production of endothelin-1 and angiotensin-II. Decreased nitric oxide 
and activation of receptors for advanced glycation end products enhance the activa-
tion of the transcription factors nuclear factor κB and activator protein 1. These fac-
tors induce the infl ammatory gene expression, with liberation of leukocyte-attract-
ing chemokines, increased production of infl ammatory cytokines, and augmented 
expression of cellular adhesion molecules. Secondly, hyperglycemia activates protein 
kinase C, receptors for advanced glycation end products, and nuclear factor κB in 
vascular smooth muscle cells. Vascular smooth muscle cells are integral in the devel-
opment of atherosclerosis by migrating into the nascent intimal lesion, replicating, 
and laying down a complex extracellular matrix. Thirdly, activation of protein kinase 
C and decreased production of platelet-derived nitric oxide also impairs platelet 
function (Beckman et al. 2002).
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2.3.3. Beyond traditional risk factors
Framingham risk scores estimate risk for persons without manifest atherosclerotic 
disease. Therefore, the scores apply essentially to primary prevention, i.e. to preven-
tion in persons without clinically established CAD. Once coronary atherosclerotic 
disease becomes clinically manifest, the risk for future coronary events regardless of 
other risk factors is much higher than that for patients without CAD. In this case, 
Framingham scoring no longer applies (Grundy et al. 1999).
  Sudden death or nonfatal myocardial infarction occurs without prior recognized 
CAD symptoms in ≥25 % of patients (Myerburg et al. 1993). Approximately 40% of 
deaths from CAD occur in patients with total cholesterol levels lower than average 
for the general population (Smith 2006). Thus, in the last decade, the emphasis in 
CAD prevention has broadened from primary prevention based on single risk fac-
tors, such as hyperlipidaemia or hypertension, to the identifi cation of higher-risk 
individuals on the basis of a global risk assessment (Smith et al. 2000, De Backer et 
al. 2003). Increasing research attention has been devoted to non-invasive methods 
for measuring subclinical atherosclerotic vascular disease (Greenland et al. 2001) 
and to more recently identifi ed and less well-known factors. 
2.3.3.1. Triglycerides 
Despite more than 40 years of research the relation between TGs and CAD risk has 
been considered more or less enigmatic. A controversy has raged whether elevated TGs 
are an independent risk factor (Hulley et al. 1980) mainly due to biological and sta-
tistical problems. The measurement of total plasma TGs is hampered by considerable 
inter- and intraindividual variations (Bookstein et al. 1990). The plasma TG concentra-
tion increases and decreases throughout the day in response to food intake. TG levels 
vary considerably more than LDL and HDL cholesterol, with day-to-day variability 
being 23% for TGs, 9.5% for LDL, and 7% for HDL cholesterol (Smith et al. 1993). 
Furthermore, it has been shown, already in the 1970s, that TG levels are inversely cor-
related with HDL cholesterol levels (Schaefer et al. 1978). Usually, this strong meta-
bolic interdependence thwarts attempts to assign statistically signifi cant independence 
for these parameters. In fact, in multivariate analyses, low HDL cholesterol levels have 
been a more consistent and reliable predictor of increased CAD rates than elevated TG 
concentrations (Gordon et al. 1977, Abbott et al. 1988, Criqui et al. 1993, Wilson et 
al. 1994). Additionally, plasma TG is carried in a number of different lipoproteins, and 
the ability of different TRLs to promote atherosclerosis is not the same.
  Although the impact of elevated TG levels on CAD risk has long been a matter of 
intense debate, a bulk of evidence supporting the prognostic value of this lipid con-
stituent has been gained during the last decade (Cullen 2000). Recently, a meta-analy-
sis including 262 525 participants and 10 158 CHD cases in 29 Western prospective 
studies found highly signifi cant associations between TG values and CHD risk. How-
ever, adjustment for established coronary risk factors, especially HDL cholesterol, 
substantially attenuated the magnitude of this association (Sarwar et al. 2007).
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  The exact cellular links between elevated TGs and CAD are incompletely under-
stood. Firstly, it is proposed that rather than being actual atherogenic agents them-
selves, elevated TGs merely serve as a marker for increases in remnants of TRLs and 
that it is these latter particles that are involved in the development of atherosclerosis 
(Havel 1990, Krauss 1998, Carmena et al. 2004). Secondly, hypertriglyceridemia 
has been associated with other atherogenic lipoprotein profi les, such as low HDL 
cholesterol and the presence of small, dense LDL particles. This “lipid triad” has 
also been termed atherogenic dyslipidemia commonly seen in patients with abdomi-
nal obesity, IR, and physical inactivity, all of which carry a markedly increased risk 
of CVD (Expert panel 2002). Thirdly, elevated TGs are associated with increased 
concentrations of factor VII and plasminogen activator inhibitor-1, which may ac-
celerate the thrombotic processes (Krauss 1998).
2.3.3.2. Postprandial lipemia
2.3.3.2.1. Epidemiological and case-control studies
Zilversmit introduced postprandial lipemia as a putative atherogenic factor in 1979 
(Zilversmit 1979). Since then growing evidence have indicated that postprandial 
TRLs play a role in the development of CAD. The mechanisms of atherogenicity 
have, however, remained poorly understood.
  Several case-control studies, with mainly total TGs as postprandial lipid outcome 
variable, have suggested that patients with angiographically verifi ed CAD have greater 
postprandial lipemia than control subjects (Simons et al. 1987, Simpson et al. 1990, 
Groot et al. 1991, Patsch et al. 1992, Syvänne et al. 1994a, Weintraub et al. 1996, 
Karpe et al. 1999). The magnitude of postprandial lipemia has also been related to 
the angiographic 5-year progression of CAD in young post-infarction patients (Karpe 
et al. 1994). Of note, there is a lack of results from prospective studies.
2.3.3.2.2. Determinants of postprandial lipemia
The magnitude of postprandial lipemia is closely correlated with fasting TG concen-
trations (Denborough 1963, Redgrave et al. 1979, Wilson et al. 1985, O´Meara et 
al. 1992). This mostly refl ects the competition between elevated levels of endog-
enous VLDL and intestinally-derived CMs because both classes of particles share, at 
least partly, common removal mechanisms (Brunzell et al. 1973, Chen et al. 1991). 
Age appears to affect postprandial lipemia. Older subjects have higher postprandial 
TG levels than younger ones (Cohn et al. 1988, Krasinski et al. 1990). This could be 
due to prolonged residence time of CM remnants (Cohn et al. 1988) and to an in-
creased VLDL production rate (Millar et al. 1995). Obesity, especially accumulation 
of visceral fat, is linked with postprandial lipemia even in normolipidemic subjects 
(Lewis et al. 1990, Couillard et al. 1998, Mekki et al. 1999). This may partly be 
related to differences in fasting TG concentrations between obese and lean subjects 
(Lewis et al. 1990). Regular exercise decreases postprandial lipemia (Nikkilä et al. 
1962, Merril et al. 1989, Hartung et al. 1993).
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2.3.3.2.3. Quantifi cation of postprandial lipemia
Accurate quantifi cation of remnant lipoproteins is problematic. Firstly, remnants are 
diffi cult to differentiate from their larger and more TG-rich precursors. Secondly, 
plasma concentration is low due to their rapid catabolism. Thirdly, they are bio-
chemically diffi cult to isolate or detect because they are heterogeneous in size and 
composition (Cohn et al. 1999). To circumvent these problems, different methods 
for studying postprandial TRL metabolism have been employed.
  The traditional method for isolating remnants has been ultracentrifugation allow-
ing isolation of lipoproteins intermediate in density (1.006<d<1.019 g/mL, Sf 12-
20) between VLDL and LDL. There is, however, no standardized clinical procedure 
for measurement of IDL concentration. Usually, IDL has been determined from 
simultaneously centrifuged sample of plasma, as the difference between cholesterol 
in the d>1.006 and d>1.019 g/mL fractions. However, this IDL fraction does not 
include larger, more TG-rich, less completely catabolized remnants (small VLDLs, 
Sf 20-60), which have also been shown to be atherogenic (Cohn et al. 1999) 
  Plasma lipoproteins have also routinely been separated according to their charge 
by agarose gel electrophoresis. Large TRLs or CMs remain at the origin of the 
gel, while ultracentrifugally isolated VLDLs (d<1.006 g/mL) normally migrate as 
a single band with pre-β mobility. Smaller, less TG-rich VLDLs are less negatively 
charged and migrate with slower mobility. TRL remnants are intermediate in size 
between VLDL and LDL and have been separated as “midband lipoproteins” by 
polyacrylamide tube or gradient gel electrophoresis. Several clinical studies on post-
prandial lipoprotein metabolism have utilized vitamin A to trace intestinal CM and 
their remnants. The rationale for this approach is that dietary vitamin A is incor-
porated into these particles as retinyl esters, mainly retinyl palmitate, which remain 
within the CM particle throughout its metabolism. This method is, however, not 
ideal because intestinal absorption of vitamin A is variable. Second, it does not al-
low assessment of the hepatic apoB-100 particles, and thirdly, retinyl esters can be 
detected in apoB-100 containing TRLs and in LDL and HDL at later postpranidal 
times (Cohn et al. 1999).
  Although these techniques have provided important information on TRL rem-
nants, they are complex, time consuming, and not optimal for use in clinical practice. 
Therefore, a more convenient method for isolation and quantifi cation of remnant li-
poproteins was developed in 1993 (Nakajima et al. 1993). In this assay, remnant lipo-
protein particles (RLPs) are separated from plasma by immunoaffi nity chromatography 
with a gel containing an anti-apoA-I and a specifi c apoB-100 monoclonal antibody. 
The former antibody recognizes all HDL and any newly synthesized CMs containing 
apoA-I, whereas the latter antibody recognizes all apoB-100-containing lipoproteins, 
except for certain particles enriched in apoE. Thus, HDLs, LDLs, large CMs, and the 
majority of VLDLs are retained by the gel. The unbound RLPs are made up of TRLs 
containing apoB-48 and a subfraction of apoB-100. RLPs are routinely measured in 
terms of the cholesterol content (RLP-C), although they can also be quantifi ed in 
terms of TGs (RLP-TG) or specifi c apolipoproteins (Marcoux et al. 1998).
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2.3.3.2.4. Determinants of remnant lipoprotein particles 
Plasma levels of RLP-C in healthy, normolipidemic whites typically range from 0.16 
to 0.24 mmol/L (6.2 to 9.3 mg/dL). RLP-C levels in Japanese subjects have con-
sistently been reported to be lower than those in Caucasians. This may refl ect ethnic 
differences or differences in the calibration of RLP-C assays in different laboratories. 
Higher levels of RLP-C have been demonstrated in men versus women, older versus 
younger, postmenopausal versus premenopausal women, the fed versus the fasted 
state, individuals with DM, and in patients with familial dyslipidemia (Twickler et al. 
2004). Plasma concentration of RLP-C has shown to signifi cantly correlate with the 
plasma concentration of total TG, VLDL triglyceride, and VLDL cholesterol, but 
not with LDL cholesterol (Cohn et al. 1999).
2.3.3.2.5. Remnant lipoprotein particles and CAD
Several epidemiologic studies have shown associations between RLP elevations and 
CAD (Devaraj et al. 1998, Takeichi et al. 1999, Kugiyama et al. 1999, Masuoka et al. 
2000, McNamara et al. 2001, Fukushima et al. 2001). In 135 Japanese patients with 
CAD (Kugiyama et al. 1999), elevated RLP levels were an independent predictor of 
future coronary events. Two angiographic studies (Devaraj et al. 1998, Masuoka et 
al. 2000) have revealed that patients with signifi cant lesions have higher RLP-C levels 
than patients without signifi cant lesions. In contrast, in the fi rst long-term prospective 
investigation recently conducted in a cohort of 1156 Japanese-American men from the 
Honolulu Heart Program, RLP levels did not provide additional information about 
CHD incidence as compared with concentration of total TGs. This could be attributed 
to the strong correlation between RLP levels and total TGs (Imke et al. 2005). 
2.3.3.3. LDL particle size
Small, dense LDL particles bind less avidly to the LDL receptor than large, buoyant 
LDL resulting in decreased hepatic clearance and a longer residence time in plasma. 
The fi ltration rate of LDL particles into the arterial intima is inversely related to 
particle size. Therefore, small, dense LDL particles enter the arterial wall more eas-
ily (Chapman et al. 1998). Moreover, small, dense LDL particles show greater sus-
ceptibility to oxidation than large LDL (de Graaf et al. 1991, Tribble et al. 2001). 
Together, these fi ndings have led to the hypothesis that small, dense LDL is a potent 
atherogenic lipoprotein. 
  Several lines of evidence obtained from both cross-sectional and prospective 
studies suggest that the predominance of small, dense LDL is associated with an 
increased risk of CAD (Rizzo et al. 2006). This has indeed been shown in the vast 
majority of univariate analyses, but after multivariate adjustment for confounding 
variables, in particular TGs and HDL cholesterol, LDL particle size is seldom a 
signifi cant and independent predictor of CAD risk (Rizzo et al. 2006). Hence, it 
has been argued that LDL subclass measurement does not add information beyond 
measuring TG levels and LDL and HDL concentrations (Sacks et al. 2003). 
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  The small, dense LDL phenotype rarely occurs as an isolated disorder. It is fre-
quently accompanied by hypertriglyceridemia and low HDL cholesterol. These 
three abnormalities are metabolically intertwined and thus, it is not easy to single 
out small, dense LDLs as independent risk factors for CAD (Lada et al. 2004). Of 
note, there is only one study to date, which has demonstrated a shift in LDL particle 
size towards smaller, densier species during alimentary lipemia in patients with CAD 
(Koba et al. 2005). 
  Interestingly, recent studies have shown that the overall number of LDL par-
ticles in plasma, not their size, may provide a better indication of the risk of CAD 
(Lada et al. 2004). The number of LDL particles in plasma is potentially important, 
because the arterial walls are exposed to these particles, and an increased number 
might increase atherogenicity independently of particle size (Rizzo et al. 2006).
2.3.3.4. Oxidized LDL 
2.3.3.4.1. Origin of the oxidative modifi cation hypothesis
The oxidative modifi cation hypothesis of atherosclerosis was proposed in 1989 
(Steinberg et al. 1989). According to this hypothesis, oxidative modifi cation of LDL 
is necessary and possibly obligatory in the development of atherosclerotic lesions. 
The original interest stemmed from seminal observations that native LDL was not 
taken up by macrophages rapidly enough to generate foam cells. It was postulated 
that circulating LDL must undergo some kind of structural modifi cation before it 
becomes proatherogenic. Further, it was proposed that, the uptake of LDL into 
macrophages occurs through “scavenger” receptors rather than the classic LDL re-
ceptor (Goldstein et al. 1979). Since then, multiple studies in experimental animal 
models have provided fi rm evidence of an important role of oxLDL in atherogenesis 
(Berliner et al. 1996, Steinberg 1997, Chisolm et al. 2000). However, the exact in 
vivo mechanisms of LDL oxidation in humans are still unknown. 
2.3.3.4.2. Biological activities of oxLDL
OxLDL has a wide range of atherogenic properties, from early lesion formation 
to plaque rupture. It contributes to atherogenesis by 1) inducing endothelium to 
express adhesion molecules for monocytes, intercellular adhesion molecule-1, and 
vascular adhesion molecule-1, 2) increasing monocyte chemotaxis and adhesion, 
3) compromising endothelial function through inhibition or reduced production 
of nitric oxide, 4) upregulating infl ammatory genes and growth factors, and 5) 
stimulating growth of smooth muscle cells, platelet aggregation, and thrombus 
formation (Tsimikas et al. 2001). OxLDL also stimulates an immunological re-
sponse seen as autoantibodies against several epitopes of oxLDL (Chisolm et al. 
2000). Finally, the uptake of oxLDL via scavenger receptors leads to massive depo-
sition of lipids into the macrophages, i.e. the formation of foam cells. Foam cells 
form the core of the earliest atherosclerotic lesion, the fatty streak.
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  There is substantial evidence that oxLDL is present in vivo within atheroscle-
rotic but not normal blood vessels (Ylä-Herttuala et al. 1989, Witztum et al. 2001). 
LDL that is extracted from human and animal atherosclerotic lesions has all of the 
physical, chemical, immunological, and biological properties of oxLDL. Mono-
clonal antibodies to epitopes of oxLDL immunostain animal and human atheroscle-
rotic lesions. Autoantibodies against oxLDL, refl ecting the fact that oxLDL is very 
immunogenic, have been found in lesions and plasma of animals and patients with 
various manifestations of atherosclerosis (Tsimikas et al. 2001). 
2.3.3.4.3. Measurement of oxLDL
Until recently, methods for direct measurement of oxLDL in blood were lacking. 
Initially, an assay measuring the level (the titer) of autoantibodies against neo-
epitopes in LDL oxidized by copper or modifi ed by malondialdehyde, a highly reac-
tive breakdown product formed during peroxidation of polyunsaturated fatty acids 
in phospholipids and cholesteryl esters, was developed as an indirect indication of in 
vivo oxidation of LDL. Autoantibodies against oxLDL have been reported to be as-
sociated with coronary atherosclerosis. However, the data are not consistent (van de 
Vijver et al. 1996, Uusitupa et al. 1996, Orchard et al. 1999, Lehtimäki et al. 1999), 
possibly due to assay divergencies in the different studies (Mertens et al. 2001).
  Nowadays, more sensitive enzyme-linked immunosorbent assay (ELISA) meth-
ods to “directly” measure the small amount of circulating oxLDL are available. In 
these assays, different monoclonal antibodies against a neo-epitope in the aldehyde-
substituted apoB-100 moiety of oxLDL (Holvoet et al. 1998) or against an epitope 
in the oxidized phospahtidylcholine (Itabe et al. 1996) are used to recognize a single 
epitope in the circulating oxLDL. 
2.3.3.4.4. OxLDL in cardiovascular disease
To date, a number of studies in the cardiovascular fi eld have measured oxLDL levels 
by utilizing competitive ELISA. Holvoet et al. (1998) found elevated plasma concen-
trations of oxLDL in patients with stable CAD and in subjects with acute coronary 
syndromes compared with age-matched control subjects. In a Japanese case-control 
study (Toshima et al. 2000), the concentrations of oxLDL were 1.9-fold higher in 
patients with angiographically proven CAD than in healthy controls. Furthermore, 
Holvoet et al. (2001) demonstrated, in 178 patients with angiographically verifi ed 
CAD and 126 age-matched subjects, that patients with CAD had signifi cantly el-
evated plasma levels of oxLDL. 
  Elevated levels of oxLDL in vivo have also been found in patients with impaired 
glucose tolerance (Kopprash et al. 2002). Notably, it has been shown in type 2 DM 
that postprandial LDLs are oxidized more extensively in vitro than fasting diabe-
tes and control samples (Diwadkar et al. 1999). Recently, Meisinger et al. (2005) 
concluded, in a prospective population study comprising men, that oxLDL was a 
stronger predictor of risk than standard lipid variables and other traditional CAD 
risk factors. Further, Holvoet et al. (2004) found, in a population-based cohort of 
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3033 individuals aged 70-79 years at baseline, that the metabolic syndrome was 
associated with higher levels of oxLDL. However, oxLDL was not an independent 
predictor of total CHD risk. 
2.3.3.5. Paraoxonase-1 (PON1)
A large body of evidence has accrued indicating that the antioxidant property of 
HDL is largely mediated by the HDL-bound enzyme PON1 (Durrington et al. 
2001). PON1 was initially studied, more than 50 years ago, in the fi eld of toxi-
cology because of its ability to hydrolyze, and hence detoxify, organophosphates. 
The name PON refl ects its ability to hydrolyze paraoxon, a toxic metabolite of the 
insecticide parathion. Parathion is toxic to humans because of its irreversible inhi-
bition of acetyl cholinesterase (Aldrige 1953a, 1953b). In addition, paraoxonase 
hydrolyzes active metabolites of a number of other organophosphorus insecticides 
(e.g., chlorpyrifos oxon, dizoxon) as well as nerve agents such as sarin and soman 
(Costa et al. 2005). 
2.3.3.5.1. Synthesis and structure of PON-1
The human genome contains at least three PON genes, designated PON1, PON2, 
and PON3. All three genes reside on the long arm of human chromosome 7. The 
genes share about 65% similarity at the amino acid level and approximately 70% 
similarity at the nucleotide level (Primo-Parmo et al. 1996). Human PON1, so far 
the most studied of the three known PONs, is a glycoprotein comprising 354 amino 
acids with a molecular mass of about 44 kDa (Furlong et al. 1993).
  In humans, PON1 mRNA expression is mainly limited to the liver, while PON3 
mRNA is expressed in the liver and kidney, and PON2 is widely expressed in most 
tissues including the heart, kidney, liver, lung, placenta, small intestine, spleen, stom-
ach, and testis. Furthermore, unlike PON1 and PON3, PON2 is also detected in the 
cells of the artery wall, including endothelial cells, smooth muscle cells, and macro-
phages. PON1 and PON3 specifi cally associate with HDL in circulation, whereas 
PON2 is not linked to HDL (Primo-Parmo et al. 1996, Ng et al. 2005). Recently, 
PON1 was also shown to be associated with VLDL, but not with LDL (Deakin et 
al. 2005). Both human PON2 and PON3 possess antioxidant properties, similar to 
those of PON1, and are capable of preventing oxidative modifi cation of LDL (Ng 
et al. 2005). 
2.3.3.5.2. PON-1 gene
PON1 contains several polymorphic sites, i.e. two or more variants (alleles) exist at 
signifi cant frequencies in the population. One specifi c form of polymorphism is the 
single nucleotide polymorphism defi ned as a specifi c difference in one base at a de-
fi ned location of an individual´s DNA. PON1 has two single nucleotide polymor-
phisms in the coding region of the gene that change the amino acid of the protein: a 
methionine (M) to leucine (L) substitution at position 55 (M/L55) and a glutamine 
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(G) to arginine (A) substitution at position 192 (Q/R192). In addition to these two 
coding polymorphisms, at least fi ve polymorphisms have been detected in the PON1 
promoter region (Ng et al. 2005). 
  PON1 activity can vary up to 40-fold in human populations (Mueller et al. 1983, 
Richter et al. 1999). Part of this variability is explained by the Q/R192 polymor-
phism (Adkins et al. 1993). This Q/R192 polymorphism has been more widely 
studied, because the two alloenzymes have different affi nities and catalytic activities 
towards a number of substrates. The R-allele at position 192 displays several-fold 
higher activity towards paraoxon hydrolysis, whereas the Q-allele is more active to-
wards sarin, soman, and diazoxon (Aviram et al.1998a). In contrast, phenylacetate 
hydrolysis is largely unaffected by the polymorphism, and has been used as a sur-
rogate for protein concentrations (Cao et al. 1999). 
2.3.3.5.3. Measurement of PON-1 activity and concentration
PON1 has two qualitatively different properties, paraoxonase and arylesterase activi-
ties, because it hydrolyzes both organophosphates and aromatic esters (Mackness 
et al. 1987). Paraoxonase activity is measured from serum samples by hydrolysis of 
paraoxon to the non-toxic products, p-nitrophenol and diethyl phosphate (Aldridge 
1953, Erdös et al. 1961). The activity is fi rst measured without any added NaCl (ba-
sal activity) and then with 1 M NaCl included. The percent stimulation of paraoxo-
nase by 1 M NaCl is used to classify individuals into the non-salt-stimulated A type, 
and salt-stimulated AB and B types (Eckerson et al. 1983a), since measurement of 
paraoxonase activity alone does not clearly discriminate between AB and B pheno-
types (Flugel et al. 1978).
  Arylesterase activity is usually measured with phenylacetate as a substrate (Mounter 
et al. 1953, Simpson 1971). The distribution of arylesterase activity in a Caucasian 
population has a single mode while the paraoxonase activity is bimodally distributed. 
The distribution of the ratio of salt-stimulated paraoxonase activity to arylesterase 
activity, however, is clearly trimodal indicating the existence of three paraoxonase phe-
notypes (Eckerson 1983b). The serum PON1 concentration can be determined by 
a competitive ELISA using a monoclonal antibody (Blatter Garin et al. 1994) or by 
sandwich ELISA using two monoclonal antibodies (Kujiraoka et al. 2000).
2.3.3.5.4. Antioxidant properties of PON-1
In vitro studies have shown the ability of PON1 to block the accumulation of lipid 
peroxides in LDL (Mackness et al. 1993, Watson et al. 1995). Several studies have 
confi rmed and extended this fi nding, demonstrating that PON1 prevents the forma-
tion of oxLDL and inactivates LDL derived oxidized phospholipids once they are 
formed. PON1 also protects phospholipids in HDL from oxidation (Costa et al. 
2005). The most convincing data to link PON1 with CAD come from animal stud-
ies. In knockout mice lacking the gene for PON1, atherosclerosis develops more 
rapidly than in wild-type mice, whereas mice that overexpress human PON1 are 
resistant to atherosclerosis (Shih et al. 1998, Tward et al. 2002).
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2.3.3.5.5. PON-1 genotype and CAD
Hypothesized differences in the ability of the polymorphic forms to protect oxida-
tion of LDL have led to numerous studies attempting to determine the relationship 
between PON1 polymorphisms and CAD. The majority has reported on the PON1 
Q/R192 polymorphism, fewer studies have been conducted on the PON1 M/L55 
polymorphism. The results, no matter what the polymorphism investigated, have 
proved contradictory (Durrington et al. 2001, Wheeler et al. 2004). A recent meta-
analysis using all 43 available studies on the PON1 polymorphisms involving 11212 
CAD cases and 12786 controls suggested that the link between PON1 Q/R192 
polymorphism and CAD was at best weak (Wheeler et al. 2004). There were no 
signifi cant associations between PON1 M/L55 polymorphism and CAD. Mostly, 
CAD was defi ned as a history of myocardial infarction and/or signifi cant (≥50% of 
the luminal diameter) angiographic coronary stenosis. Quantitative coronary angi-
ography (QCA) was utilized in two studies (Turban et al. 2001, Chen et al. 2003a). 
In a report from the Women´s Ischemia Syndrome Evaluation (WISE) study includ-
ing 711 women, Chen et al. (2003a) did not fi nd any signifi cant association between 
the PON polymorphisms and stenosis severity in either white or black women. How-
ever, when patients with signifi cant CAD (≥50% stenosis) were stratifi ed into groups 
with one-, two-, or three-vessel CAD, signifi cant associations were noted between 
PON polymorphisms and the number of diseased vessels in white but not in black 
subjects. In the study by Turban et al. (2001), Q/R192 polymorphism was not as-
sociated with the progression of coronary atherosclerosis determined by serial QCA. 
Of note, this was the only prospective trial reported in the meta-analysis.
2.3.3.5.6. PON-1 activity and concentration and CAD
Investigating only an association between PON1 polymorphism and vascular disease 
may not adequately assess the protective effect of the enzyme, which has led to the 
proposal that PON1 activity and concentration rather than genotype alone may be 
more important in determining atherosclerosis risk (Mackness et al. 2001). Very 
few studies have included a measure of PON1 activity and concentration. Mackness 
et al. (2001) found in a case-control study, that PON1 activity toward paraoxon 
and PON1 concentration were lower in 417 subjects with angiographically proven 
CAD regardless of PON1 genotype. Similarly, although the difference did not reach 
statistical signifi cance, Azarisiz et al. (2003) found that PON1 activity of patients 
with CAD (n=68) was lower than that of patients without CAD (n=33) and control 
subjects (n=24). In addition, there is one prospective epidemiologic study, which 
has shown in middle-aged men that low PON1 activity toward paraoxon is an in-
dependent risk factor for coronary events (Mackness et al. 2003). However, PON1 
concentration was not related to new CAD events. The reason why only paraoxon 
hydrolytic capacity refl ected PON1 as a risk factor for CAD was unclear. 
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2.3.3.6. Apolipoprotein B
ApoB-100 is the major apolipoprotein component of the atherogenic lipoproteins 
VLDL, IDL, LDL, and Lp(a). ApoB has been proposed (Sniderman et al. 1996) 
and debated (Rader et al. 1994) as risk factor for CAD. Some studies, but not all, 
have suggested that the measurement of apoB in plasma may provide more informa-
tion on CAD risk than LDL cholesterol alone (Durrington et al. 1986, Stampfer et 
al. 1991, Rader et al. 1994). Some of these discrepancies may have resulted, in part, 
from diffi culties in standardizing assays for measuring plasma apoB levels. However, 
standardized methods have been developed (Marcovina et al. 1994) and population 
results have subsequently been reported. In fact, four large, prospective epidemio-
logic studies (Quebec Cardiovascular Study [Lamarche et al. 1996], Moss Heart 
Study [Moss et al. 1999], AMORIS Study [Walldius et al. 2001], Northwick Park 
Heart Study [Talmud et al. 2002]) have shown that apoB is superior to total or LDL 
cholesterols. In addition, the Quebec Cardiovascular Study demonstrated increased 
risk associated with small, dense LDL, while the Northwick Park Heart Study iden-
tifi ed TG and apoB as the most informative pair of lipid risk factors. The Apolipo-
protein-related Mortality Risk (AMORIS) Study, in which 98722 men and 76831 
women were followed for an average of 67 months, LDL cholesterol was predictive 
in men, but not in women. Further, LDL cholesterol was predictive of risk in those 
<70 years, but it was not predictive in those >70 years of age. By contrast, apoB 
was predictive in both men and women, and both above and below the age of 70. 
The AMORIS Study suggests that apoB should be regarded as highly predictive in 
evaluating cardiac risk. Further, apoB might be of greatest value in the diagnosis and 
treatment of persons with normal or low concentrations of LDL cholesterol.
  It has recently been proposed that apoB should be included in all guidelines as an 
indicator of cardiovascular risk (Barter et al. 2006). Standardized apoB measures are 
not currently widely available in clinical practice. However, non-HDL cholesterol 
has shown to be signifi cantly correlated with apoB and can represent an acceptable 
surrogate marker (Vega et al. 1990, Abate et al. 1993). Non-HDL cholesterol, rou-
tinely calculated as total cholesterol minus HDL cholesterol, is the sum of VLDL + 
IDL + LDL cholesterols and thus, an indirect measure of atherogenic lipoproteins 
containing apoB.
2.3.3.7. Apolipoprotein E 
2.3.3.7.1. Structure and function of apoE
ApoE is a 299 amino-acid protein that is synthesized and secreted from hepatocytes 
and macrophages. The main physiological role of apoE is to mediate the interac-
tion of lipoproteins with their receptors, including the LDL receptor and the LDL 
receptor-related protein. Since it serves as a ligand for these receptors, apoE plays a 
critical role in determining the clearance of remnants of CM and VLDL (Davignon 
et al. 1999, Curtiss et al. 2000). In vitro studies have shown that apoE modulates 
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activities of lipoprotein and hepatic lipases (Wang et al. 1985). It has also been 
demonstrated that heparan sulfate proteoglycans facilitate the uptake of atherogenic 
lipoproteins by ligand transfer to LDL receptor-related protein and that apoE can 
mediate the seuquestration or trapping of the remnants by binding to heparan sul-
fate proteoglycan (Mahley et al. 1995). In addition, apoE can promote the cho-
lesterol effl ux from macrophages, thus facilitating the reverse cholesterol transport 
from peripheral tissues to liver (Lin et al. 1999). 
  The three common apoE isoforms, designated E2, E3, and E4, are encoded 
for by distinct alleles on human chromosome 19. They are distributed in six differ-
ent phenotypes ranking from most to least common E3/E3, E4/E3, E3/E2, E4/
E4, E4/E2, and E2/E2 (Davignon et al. 1999). ApoE polymorphism is estimated 
to explain 4-15% of the variation in LDL concentrations. Compared to apoE3 or 
apoE2 isoforms, the presence of apoE4 is associated with higher levels of LDL cho-
lesterol, TGs, and apoB, and lower concentrations of HDL cholesterol (Davignon et 
al. 1999, Curtiss et al. 2000). The mechanisms that are responsible for such changes 
are currently poorly understood except for the variation in cholesterol levels, where 
an action on hepatic LDL receptor levels is likely to make a major contribution 
(Mahley et al. 2000). Functionally, apoE2 has strikingly reduced affi nity in vitro for 
the LDL receptor and moderately reduced affi nity for LDL receptor-related protein, 
whereas apoE4 has somewhat increased affi nity for the LDL receptor and compara-
ble affi nity for the LDL receptor-related protein. ApoE4 preferentially distributes to 
TRLs and accelerates it uptake, thereby leading to down-regulation of hepatic LDL 
receptor expression and increased levels of LDL (Davignon et al. 1999, Mahley et al. 
2000). The concentration of apoE has been reported to be lower in apoE4 carriers 
than in those without apoE4 (Smit et al. 1988) suggesting that differencies in apoE 
concentrations could determine atherogenity linked to apoE.
  ApoE knockout mice are especially prone to atherosclerosis (Davignon et al. 
1999). Interestingly, physiological levels of apoE in mice have recently been shown 
to induce atherosclerosis regression independently of lowering plasma cholesterol 
levels (Raffai et al. 2005).
2.3.3.7.2. ApoE polymorphism and CAD
Numerous studies have investigated the relationship between apoE polymorphism 
and CAD, often yielding confl icting results. Following the observation that the 
presence of apoE4 is associated with higher LDL cholesterol levels, several studies, 
but not all, link the ε4 allele with greater risk for cardiovascular diseases (Eichner et 
al. 2002, Kolovou et al. 2003, Song et al. 2004). For example, a study comprising 
middle-aged men from nine populations estimated a 40% greater risk for mortality 
from CAD for carriers of the ε4 allele than ε2 carriers or individuals with the ε3/ε3 
genotype (Stengard et al. 1998). In contrast, data from a prospective study includ-
ing 385 incident cases and 373 controls did not support the simple view of E2 as a 
protective factor and E4 as a susceptibility factor in predicting future risk of myocar-
dial infarction (Liu et al. 2003). Nevertheless, a comprehensive recent meta-analysis 
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of 48 published studies, comprising 15492 case patients and 32965 controls, con-
cluded that carriers of the ε4 allele had a 42% higher risk for CHD compared with 
individuals with the ε3/ε3 genotype. The ε2 allele had no signifi cant association 
with CHD risk (Song et al. 2004).
2.3.3.8. Lipoprotein(a)
2.3.3.8.1. Structure and function of Lp(a)
Lp(a), fi rst described in 1963 (Berg 1963), is a complex genetic variant of LDL in 
which apoB 100 is linked by a disulfi de bond to apo(a). Apo(a) is a highly glyco-
sylated protein displaying size heterogeneity and molecular mass varying between 
300 and 800 kDa. The apo(a) gene has been localized to the long arm of chromo-
some 6 (q26-27) where it is closely linked to the plasminogen gene. The concentra-
tion of Lp(a) shows considerable inter- and intraindividual biological variation. The 
consequent inherited differences in apo(a) molecular mass are largely responsible 
for the wide range of Lp(a) concentrations in different individuals with low levels 
predominating in European populations. At least 34 phenotypes are expressed, and 
there are potentially more phenotypes and genotypes that may exist. The apoE phe-
notype has also been suggested to play part in determining Lp(a) concentrations, 
the lowest levels being associated with the apoE2 phenotype and the highest with 
the apoE4 phenotype. In addition, Lp(a) levels can be modifi ed by disease, par-
ticularly renal disease. Chronic renal failure or proteinuria, even with relatively well 
preserved creatinine clearance, both increase the median Lp(a) level on average by 
three to four times that of matched healthy controls. Lp(a) is associated with athero-
sclerosis in chronic renal failure (Durrington 1995). The similarity of Lp(a) to LDL 
and plasminogen has generated considerable interest, and proposed mechanisms of 
accelerated atherothrombosis caused by high levels of Lp(a) are shown in Table 2.
Table 2. Mechanisms of accelerated atherothrombosis caused by high levels of 
Lp(a).
Is readily oxidized and forms highly atherogenic particles with LDL
Enhances oxidation, uptake, and retention of LDL
Promotes lipid uptake by macrophages
Enhances expression of intercellular adhesion molecules
Increases smooth muscle cell proliferation and migration
Competes with plasminogen for binding to receptors in platelets, fi brin, endothelial- 
and mononuclear cells
Inhibits tissue plaminogen activator and enhances production of plasminogen activator 
inhibitor 
Increases formation of thrombin
Decreases plasmin formation and impairs fi brinolysis
Adapted from Enas et al. (2006). 
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2.3.3.8.2. Lp(a) and CAD
Among numerous retrospective case-control studies, virtually all have shown an as-
sociation between elevated Lp(a) levels and CAD (Marcovina et al. 1998). In con-
trast, several prospective studies have yielded apparently confl icting results, ranging 
from a strongly positive association to no association at all (Marcovina et al. 1998). 
Nevertheless, a meta-analysis (Danesh et al. 2000), including 27 prospective studies 
with information on 5436 CAD cases observed during mean follow-up of 10 years, 
supported an independent predictive power for elevated Lp(a). These prospective 
studies of CAD generally reported little or no change in risk ratios after adjust-
ment for other risk factors. This suggests that any effects of Lp(a) are unlikely to 
be accounted for by effects on, or confounding with, classical vascular risk factors 
(Danesh et al. 2000). Further, the Prospective Epidemiological Study of Myocar-
dial Infarction (PRIME), a recently conducted cohort study comprising 9133 men 
from France and Northern Ireland with no history of CHD or use of hypolipidemic 
drugs, confi rmed Lp(a) as a predictor of CHD risk (Luc et al. 2002).
2.3.3.9. Insulin resistance 
2.3.3.9.1. Overview
IR, characterized by a diminished response to the biological effects of insulin, is a 
strong predictor of type 2 DM (Lillioja et al. 1993). In addition, IR has been associ-
ated with obesity, predominantly intra-abdominal distribution of fat, hypertension, 
low HDL cholesterol, and hypertriglyceridemia, all of which are well-known risk 
factors for CAD (Reaven 1988, DeFronzo et al. 1991).
2.3.3.9.2. Assessment of IR – the homeostasis model assessment
The euglycemic hyperinsulinemic clamp technique has been regarded as the reference 
method for evaluating IR. However, this method is expensive, technically complex, and 
therefore unsuitable in clinical practice. In comparison with the euglycemic clamp, the 
homeostasis model assessment (HOMA) is an easy, practical, and inexpensive method 
for assessing IR. The HOMA is a method for assessing β-cell function and/or IR from 
the basal concentrations of glucose and insulin using a simple mathematical calcula-
tion (Matthews et al. 1985). The HOMA model has been shown to correlate moder-
ately well with insulin sensitivity as measured using the euglycemic clamp technique. 
Already quoted in over 500 publications, the HOMA model has become a widely 
used tool in clinical and epidemiological research (Wallace et al. 2004).
  HOMA IR, refl ecting both peripheral and hepatic insulin sensitivity, is based 
upon the correlation between insulin and glucose values and the assumption that 
rising glucose concentrations lead to a compensatory increase in insulin concentra-
tions. Thus, HOMA IR is highly dependent on the fasting insulin level and it has 
been argued that calculating HOMA IR in normal population is no better than 
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measuring fasting insulin concentrations. Furthermore, it has been reported that 
the intraindividual variation in HOMA-derived IR is much greater in subjects with 
type 2 DM than in non-diabetic subjects (Jayagopal et al. 2002). The reasons for 
this high inherent variability may be due to the underlying biological variability in 
insulin levels, arising from the combination of its short half-life, the known cyclicity 
of insulin secretion (Matthews et al. 1983), and the rapid responsiveness to changes 
in hormonal and metabolic milieu.
2.3.3.9.3. IR and development of cardiovascular disease
Given that IR is related to cardiovascular risk factors, it seems reasonable to believe 
that IR should be strongly related to cardiovascular disease. Surprisingly, there has 
been a marked controversy about this issue (Stern 1996). Hyperinsulinemia has 
been identifi ed as a risk factor for CAD in several (Després et al. 1996, Pyörälä et 
al. 1998, Hanley et al. 2002), but not in all prospective studies (Welin et al. 1992, 
Ferrara et al. 1994, Orchard et al. 1994, Resnick et al. 2003). The Helsinki Police-
men Study showed that hyperinsulinemia was associated with an increased CHD risk 
over a 22-year follow-up in men (Pyörälä et al. 1998). In the San Antonio Heart 
Study, where a population cohort was studied between 1984-1988 and followed up 
7 years later, IR as calculated by the HOMA was associated with an increased CVD 
incidence independently of several cardiovascular covariates (Hanley et al. 2002). In 
contrast, in a study among non-diabetic American Indians, IR estimated by HOMA 
predicted DM, but did not predict CVD independently of other risk factor (Resnick 
et al. 2003). Further, the negative studies by Welin et al. (1992) and Ferrara et al. 
(1994) were done in elderly subjects and thus could have represented a survival bias. 
The study by Orchard et al. (1994) was done in high-risk subjects and thus its study 
population might have been enriched in subjects with IR.
2.3.3.9.4. IR and coronary atherosclerosis
Results from cross-sectional studies about the association between IR and the angi-
ographic characteristics of coronary atherosclerosis estimated by conventional coro-
nary angiography have yielded apparentely confl icting results (Bressler et al. 1996, 
Sasso et al. 2004, Yanase et al. 2004, Satoh et al. 2005). In a small study comprising 
13 subjects with normal glucose tolerance, IR, as measured by the clamp technique, 
was positively correlated with the severity of CAD (Bressler et al. 1996). Sasso et 
al. (2004) showed that, in 234 men with normal glucose tolerance, the number of 
stenosed coronary vessels was correlated with HOMA IR. Moreover, Yanase and 
colleagues (2004) reported that HOMA IR was an independent risk factor of a 
new cardiovascular event in 102 patients with prior CAD and normal glucose toler-
ance. In contrast, Satoh et al. (2005) did not fi nd a signifi cant relationship between 
HOMA IR and the number of diseased coronary arteries, although post-challenge 
hyperinsulinemia showed a relation with the severity of CAD.
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2.3.3.9.5. Atherogenic properties of IR
Data suggest that high amounts of fat tissue and derangements of the adipose tis-
sue metabolism are the primary factors predicting the development of IR (Ruan et 
al. 2004). Adipose tissue is a complex and highly active metabolic and endocrine 
organ. Several adipocyte-derived proteins, such as tumor necrosis factor α, inter-
leukin-6, tissue factor, and plasminogen activator inhibitor-1, have been implicated 
in the pathogenesis of obesity and IR (Kershaw et al. 2004). Adiponectin is the 
only adipocyte-derived hormone that is known to increase insulin sensitivity in the 
liver and skeletal muscle (Kadowaki et al. 2005). Kadowaki et al. (2005) showed 
that genetic factors in the adiponectin gene itself and environmental factors causing 
obesity such as a high-fat diet reduced adiponectin levels. They proposed that reduc-
tion of adiponectin might play a crucial causal role in the development of IR, type 
2 DM, and atherosclerosis. Indeed, a low level of adiponectin has been shown to be 
associated with the prevalence of CAD, and to predict the occurrence of myocar-
dial infarction (Nakamura et al. 2004, Pischon et al. 2004). Interestingly, Mazurek 
et al. (2003) demonstrated that epicardial adipose tissue in 55 patients undergo-
ing elective coronary artery bypass grafting, exhibited signifi cantly higher levels of 
chemokines (monocyte chemotactic protein-1) and several infl ammatory cytokines 
(interleukin-6, interleukin-1β, and tumor necrosis factor α) than subcutaneous fat. 
In addition, the presence of infl ammatory mediators in the tissues surrounding epi-
cardial coronary arteries was noted irrespective of DM, obesity, or chronic therapy 
with statins.
  The endothelium plays a vital role in vascular tone regulation through the re-
lease of both powerful vasodilating (e.g., nitric oxide) and vasoconstricting (e.g., en-
dothelin-1) substances (Yanagisawa et al. 1988). In healthy subjects insulin is known 
to have a direct vasodilatory effect by stimulating endothelial production of nitric 
oxide (Kuboki et al. 2000). In insulin-resistant individuals, however, the ability of 
insulin to stimulate production of nitric oxide is diminished. Moreover, chronic 
exposure to insulin causes coronary vasoconstriction by increasing the release of 
endothelin-1 and sympathetic nerve activity (Sundell et al. 2003).
  Endothelial dysfunction, an imbalance between endothelium-derived vasodila-
tive and vasoconstrictive factors, is regarded as an early pivotal event in atherogenesis 
and cardiovascular disease and is closely linked to obesity and IR (Steinberg et al. 
1996). In addition, obesity, IR, and endothelial dysfunction coexist and they can all 
be identifi ed in individuals with type 2 DM as well as in various groups at risk for 
type 2 DM, such as individuals with impaired glucose tolerance, family history of 
type 2 DM, hypertension, and dyslipidemia (Caballero et al. 2003). Recently, Prior 
and co-workers (2005) demonstrated that, even in the absence of traditional coro-
nary risk factors, the greatest loss in nitric oxide-mediated, endothelium-dependent 
fl ow occurred when IR was the only abnormality, and this seemed to worsen pro-
gressively with more severe states of IR.
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2.4. Quantifi cation of atherosclerosis
2.4.1. Coronary angiography
First performed by Sones in the late 1950s (Sones 1959), coronary angiography has 
subsequently become one of the most widely used invasive procedures in cardiovas-
cular medicine. Although angiographic and imaging techniques have advanced over 
the past four decades, the analysis of coronary angiograms, by visually estimated 
percent diameter stenosis (PDS), has remained unchanged in most clinical catheteri-
zation laboratories.
  Coronary angiography is used to establish the presence or absence of coronary ste-
nosis, defi ne therapeutic options, and determine prognosis in patients with symptoms 
or signs of ischemic CAD. The limitations of coronary angiography in the evaluation 
of the severity and extent of CAD are well recognized (de Feyter et al. 1991). An 
angiographic image is a two-dimensional shadowgram of an opacifi ed vessel lumen 
providing only a measure of residual lumen or relative stenosis. However, atheroscle-
rotic changes in the arterial wall are not reliably or precisely refl ected by changes in the 
lumen. Necropsy studies demonstrate that CAD is frequently diffuse and contains no 
truly normal segment (Schwartz et al. 1975, Hutchins et al. 1977, Arnett et al. 1979). 
In the presence of diffuse disease, calculation of the angiographic percent stenosis will 
predictably underestimate disease severity. 
  Angiography is often confounded by the phenomenon of arterial remodeling. 
Compensatory enlargement of the vessel wall results in preservation of nearly normal 
lumen cross-sectional area so that angiography severely underestimates or is unable to 
detect early stages of coronary atherosclerosis (de Feyter et al. 1991). Once the plaque 
enlarges to >40% of the total vessel cross-sectional area, the artery no longer enlarges, 
and the lumen narrows as the plaque grows (Glagov et al. 1987).
  Furthermore, conventional visual evaluation of the severity and extent of coro-
nary obstructions is known to be greatly associated with high inter- and intraob-
server variability (Zir et al. 1976, Marcus et al. 1988, Goldberg et al. 1990). In 
general, visual assessment leads to overestimation of the degree of narrowing in 
severe lesions and to underestimation of the severity of mild to moderate lesions 
(Fleming et al. 1991).
  Interpretation of the severity and extent of CAD is hampered by variation among 
methods of classifi cation of CAD phenotype (Selzer 1982, Gensini 1983). The defi -
nition of CAD severity was earlier based on descriptive terms such as: “marked” 
“signifi cant” “mild” “moderate” “severe” (Waller et al. 1980). The traditional one-,
two-, and three-vessel classifi cation has also been considered inadequate (Selzer 
1982). In addition, various semi-quantitative scoring systems have been used to 
make reporting on CAD severity more consistent (Gensini 1983, Moise et al. 1988, 
Sullivan et al. 1990).
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  In general, analysis of two or more orthogonal projections has been recom-
mended to allow a more accurate assessment of the severity of lesions. However, ad-
equate orthogonal views are frequently unobtainable due to vessel foreshortening, 
overlapping side branches, poor image quality, or disease at bifurcation sites (Topol 
et al. 1995). Videodensitometry is theoretically less vulnerable to inaccuracies. With 
this method, the contrast density of a selected reference segment is compared with 
the contrast density in the region of a stenosis. The major advantage of videodensi-
tometry is that lesion eccentricity and irregularity can be accounted for without the 
need for multiple image projections. It requires, however, homogeneous complete 
opacifi cation of the lumen and the clinical value of videodensitometry remains con-
troversial (Alfonso 2000).
2.4.2. Computer-based quantitative coronary angiography
Computer-assisted quantitative analysis of coronary angiograms was developed to 
overcome the limitations of visual interpretation. Originally described in the late 
1970s (Brown et al. 1977), QCA has rapidly displaced visual analysis in interven-
tional studies and also in the estimation of the progression or regression of CAD 
(Reiber et al. 1993).
In terms of accuracy and reproducibility, QCA is superior to visual analysis of coro-
nary angiograms. Variability in repeated measures of PDS or in absolute coronary 
dimensions using several different computer algorithms has shown minimal inter- or 
intraobserver variability (Brown et al. 1977, Cashin et al. 1984, Reiber et al. 1993). 
In a comparison between a panel with three readers and QCA, the latter method 
identifi ed and measured diameter stenoses between 21% and 40%, which were not 
identifi ed by the panel (Mack et al. 1992). A change of 20% in PDS has been shown 
to represent true progression or regression of coronary atherosclerosis with more 
than 95% confi dence in QCA (Syvänne et al. 1994b).
  Online computer-based QCA is possible with modern digital angiography equip-
ment, and provides a tool in diagnostic and/or therapeutic decision making during 
the catheterization procedure. Offl ine methods for QCA are useful especially for sci-
entifi c purposes. When cineangiograms recorded on fi lm are used in computer-based 
QCA analysis, they fi rst need to be transformed into digital information. Briefl y, the 
subsequent steps of this analysis are: calibration of the image data, defi nition of 
coronary segment to be analyzed, and automated detection of the arterial contours, 
with or without user-defi ned corrections (Reiber et al. 1993).
  Calibration needs to be carried out prior to analysis to allow measurement of ab-
solute vessel dimensions. This procedure, that yields a calibration factor, is based on 
the known French catheter size and on measurement of the contrast-fi lled catheter 
with use of automated edge detection of this catheter. The fi rst step in the actual 
coronary measurement is to defi ne the start- and end-point of the segment under 
analysis. After that, the arterial contours are detected by the software, and thereafter 
several clinically relevant parameters are automatically calculated (Figure 5).
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  Neither visual nor computer-assisted techniques can correct for the inherent 
limitations of a silhouette technique. Coronary intravascular ultrasound (IVUS), 
developed over the past decade, has many potential advantages in characterizing the 
atherosclerotic disease process. IVUS is a catheter-based technique, which provides 
real-time high-resolution images allowing precise tomographic assessment of lumen 
area, plaque size, and composition of a coronary segment (Topol et al. 1995).
Figure 5.  A fi nal results page of QCA-CMS® analysis of the mid-part of a right coro-
nary artery. In the upper panel and the lower left panel are the automatically detected 
luminal contours, the computer-defi ned reference contours, and the diameter function. 
In the right lower panel, the results page of the QCA analysis displayed with all detailed 
quantitative data. The percent diameter stenosis here was 61%.
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2.4.3. Ultrasonographic measurement of carotid artery
intima-media thickness (IMT)
2.4.3.1. Overview 
Over the past decade, the measurement of carotid IMT using high resolution B-
mode ultrasonography has emerged as a method of choice for determining the 
anatomic extent of atherosclerosis and for assessing cardiovascular risk. B-mode ul-
trasonography is a relatively simple, inexpensive, and non-invasive method for deter-
mining atherosclerosis. Unlike angiography, ultrasound allows imaging of all stages 
of atherosclerosis including also early arterial vessel wall changes.
2.4.3.2. Measurement of carotid IMT
Ultrasound imaging cannot discriminate between the intima and the media of the 
vessel wall because of insuffi cient axial resolution (Simon et al. 2002). Therefore, the 
combined thickness of the intima and media, the intima-media complex, is widely 
applied. Notably, this approach does not entirely exclude the possibility of fi bromus-
cular hypertrophy of the arterial media behind an increased carotid IMT (Glagov 
et al. 1988). In fact, hypertension has been shown to increase IMT independent of 
typical atherosclerotic changes, probably because of medial hypertrophy (Roman et 
al. 1995).
  Current ultrasound instrumentation with transducers ≥8 MHz are capable of 
identifying the two-parallell echogenic lines (double line pattern), which correspond 
to the interfaces between vessel lumen and the intima as well as between the media 
and the adventitia. The thickness of the echogenic line next to the vascular lumen 
added to the thickness of the adjacent dark layer compose the IMT both at the near 
wall (NW) and at the far wall (FW). The screening examination is performed bilater-
ally on the extracranial carotid artery segments. These segments are the distal straight 
1 cm of the common carotid arteries, the carotid bifurcations, and the proximal 1 cm 
of the internal carotid arteries (Greenland et al. 2001) (Figure 6 A-B).
  The validity of the FW IMT measurements has been shown by comparing the 
IMT obtained by ultrasound imaging with the IMT determined by microscopy in 
pathologic evaluation (Pignoli et al. 1986, Wendelhag et al. 1991, Wong et al. 1993). 
In the NW measurement, IMT is 80% of the histological thickness, and a difference 
of 0.02 mm is present when comparing the NW and FW measurements (Kanters et al. 
1997). Thus, the validity of NW measurements can be debated for several reasons.
  An echo is produced by tissue interfaces with a suffi cient difference in acoustic im-
pedance. The anatomical location of a structure is determined by the leading edge (the 
upper edge) of the echo. Thus, thickness of an anatomical structure is defi ned as the 
distance between the leading edges of two different echoes. Normally, the adventitia is 
quite echogenic in contrast to the media. In the FW the interface between lumen and 
intima and the media-adventitia, respectively, are visualized. In the NW, the intima-lu-
men interface is usually well defi ned. The bright echoes produced by the adventitia, 
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however, overlap the echo originating from the adventitia-media interface, which can-
not therefore be accurately visualized (Wendelhag et al. 1991). Moreover, the preci-
sion of the NW IMT depends on the axial resolution of the equipment used and on 
the gain setting (the higher the axial resolution, the more precise the measurement, 
the higher the gain, the lower the axial resolution) (Wendelhag et al. 1991). Although 
there is a small systematic difference between the NW and FW measurements, the an-
nual IMT progression rates do not differ between the NW and the FW. In addition, 
including NW measurements reduces the variability of progression. Thus, combined 
measurements might enhance precision without loss of validity (Kanters et al. 1997).
Figure 6 A-B. Schematic (A) illustration of the echoes seen in B-mode ultrasound images 
(B) of carotid artery. See text (chapter 2.4.3.) for explanation. NW; near wall, FW; far 
wall, ICA; internal carotid artery, CB; carotid bulb, CCA; common carotid artery.
Numbers indicate the acoustic interfaces as follows: 1. periadventitia-adventitia, 2. adven-
titia-media, 3. intima-lumen, 4. lumen-intima, 5. media-adventitia, 6. adventitia-periad-
ventitia. The distance between points 2 and 3 corresponds to the NW- and between points 
4 and 5 to FW IMT.
Modifi ed and used with permission from Kati Ylitalo, Doctoral Thesis 2001.
A.                                            B.
  Two main approaches are used for measuring IMT. Firstly, measurement can 
be restricted to the FW of the distal segment of the common carotid artery. This 
superfi cial and straight segment offers the best geometric conditions for obtaining 
high precision and reproducibility rate of ultrasound IMT measurement. IMT is not 
measured at a single point but averaged on approximately 100 points of measure 
along at least 1 cm of longitudinal length of the vessel. Notably, in the carotid artery, 
atherosclerotic lesions occur later in the common carotid artery than in the internal 
carotid artery or in the bifurcation (Solberg et al. 1971). Therefore IMT, when 
measured in the distal common carotid artery free from intrusive atherosclerotic 
plaque, may not be the most appropriate segment to study if the objective is focused 
on atherosclerosis (Simon et al. 2002). Secondly, IMT can be measured in the near 
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and far walls of the three main segments of extracranial carotid arteries (common 
carotid artery, carotid bifurcation, and internal carotid artery) on both sides. For 
each segment, ultrasound scan is performed in more than one direction, the maxi-
mal value of IMT is selected, and the fi nal IMT considered is the average of IMT 
values at the multiple sites examined. Measurement of IMT at multiple carotid sites 
frequently incorporates plaque thickness because plaques are common in the carotid 
bifurcation and internal carotid artery. This explains why the measured IMT can be 
regarded as a marker of early carotid atherosclerosis (Simon et al. 2002). 
2.4.3.3. Normal values of carotid IMT
In general, greater IMT values are associated with greater cardiovascular risk. For 
example, a recent meta-analysis found that the future risk of myocardial infarction in-
creases by 10% to 15% and the stroke risk by 13% to 18% for each 0.1 mm increase in 
carotid IMT (Lorenz et al. 2007). Despite this continuous relationship between IMT 
and risk, there is no clear cut-off point for the defi nition of an abnormally high IMT. 
IMT increases with age and is generally thicker in men than in women (Cheng et al. 
2002). Accordingly, designation of what is abnormal must consider at least these basic 
issues. The normal values of carotid IMT have generally been established on the basis 
of the distribution of IMT values (histogram) within a general healthy population. 
Hence, the upper normal limit used for defi ning normal range of IMT is arbitrary 
and is frequently set at the age-adjusted 75th upper percentile of the IMT distribution. 
The epidemiological data currently available indicate that a value of carotid IMT at or 
above 1 mm at any age is associated with a signifi cantly increased risk of  myocardial 
infarction and/or cerebrovascular disease (Simon et al. 2002). 
2.4.3.4. Carotid IMT and cardiovascular risk factors
In observational and epidemiological studies conducted in the general population 
traditional risk factors, such as ageing, male sex, hypertension, elevated total and 
LDL cholesterol levels, low HDL cholesterol level, DM, and smoking are associated 
with increased carotid IMT (Salonen et al. 1991, Crouse et al. 1996, Gariepy et al. 
1998, Lakka et al. 1999, Espeland et al. 1999).
  Numerous studies have investigated the association between carotid IMT and 
new or emerging risk factors. In general, data on the relationship between PON1 
Q/R192 polymorphism and carotid IMT have been negative in healthy individuals 
(Schmidt et al. 1998, Dessi et al. 1999, Markus et al. 2001) or in type 2 diabetic 
subjects (Cao et al. 1998). Likewise, the results on the connection between carotid 
IMT and PON1 activity and concentration have been confl icting (Jarvik et al. 2000, 
Valabhji et al. 2001, Campo et al. 2004).
  A link between IR and carotid IMT has been addressed in several studies, but 
the results are contradictory (Suzuki et al. 1996, Shinozaki et al. 1997, Ishizaka et 
al. 2003). Studies on the relation between carotid IMT and Lp(a) have yielded con-
fl icting results (Schreiner et al. 1996, Grebe et al. 2006). A positive relationship be-
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tween carotid IMT and ε4 allele has been shown in some studies (Terry et al. 1996, 
Cattin et al. 1997, Elosua et al. 2004), although others have failed to fi nd such a 
relationship (Slooter et al. 2001, Fernandez-Miranda et al. 2004).
  Moreover, a signifi cant association between LDL particle size and carotid IMT 
has been shown in middle-aged healthy subjects (Skoglund-Andersson et al. 1999, 
Hulthe et al. 2000a), but not in subjects with hypercholesterolaemia (Hulthe et al. 
2000b) or with CAD risk among elderly subjects (Mykkänen et al. 1999). Similarly, 
the data on associations between carotid IMT and circulating oxLDL or autoantibod-
ies against oxLDL have been inconsistent (Salonen et al. 1992, Uusitupa et al. 1996, 
Hulthe et al. 2002, Wallenfeldt et al. 2004, Mayr et al. 2006). Increased carotid IMT 
has been associated with postprandial lipidemia (Karpe et al. 1998, Boquist et al. 
1999, Karpe et al. 2001).
2.4.3.5. Carotid IMT and cardiovascular disease
Several large-scale prospective studies in general population have examined the re-
lationship between carotid IMT and the incidence of cardiac and cerebrovascular 
events. A recent meta-analysis based on data from 37 197 subjects, who were fol-
lowed up for a mean of 5.5 years, fully supports the impact of increased carotid IMT 
as an independent predictor of future vascular events (Lorenz et al. 2007).
  Carotid IMT has been employed to assess the potential therapeutic impact of 
statins on the progression of carotid atherosclerosis. Indeed, a recent meta-analysis, 
including seven placebo-controlled clinical trials of statins, reports that statin therapy 
was associated with an average decrease of IMT progression of 0.012 mm/year with 
95% confi dence interval [-0.016, -0.007]. More importantly, the meta-analysis yields 
a signifi cant odds ratio of 0.48 [0.30, 0.78] for the reduction of cardiovascular events 
associated with statin therapy (Espeland et al. 2005).
  The positive association between carotid IMT and angiograhic measures of CAD 
has been addressed in numerous studies, but the results have been contradictory (Wof-
ford et al. 1991, Tanaka et al. 1992, Adams et al. 1995, Lekakis et al. 2000, Holaj et 
al. 2003). Wofford et al. (1991) found in 843 patients undergoing coronary angiogra-
phy for clinical purposes a strong relation between extent of carotid atherosclerosis, as 
measured by B-mode ultrasound, and extent of coronary atherosclerosis, as measured 
by visual interpretation of coronary angiograms. Adams et al. (1995) concluded, in 
350 subjects referred for coronary angiography, that carotid IMT and angiographi-
cally assessed extent and severity of CAD is only weakly correlated.
  Only a few studies (Blankenhorn et al. 1993, Herrington et al. 1994, Mack et 
al. 2000) have examined the correlation between carotid IMT and CAD utlilizing 
quantitative imaging. Again, results from these studies have been confl icting. Her-
rington et al. (1994), who examined 86 patients with the B-mode score (mean of the 
maximum IMT at 12 sites) and QCA (percent diameter stenosis), found a correlation 
coeffi cient of r=0.27. Moreover, Mack et al. (2000), who investigated 188 non-smok-
ing males with prior coronary artery bypass grafting, found no signifi cant correlations 
between common carotid artery IMT and QCA measures.  
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3. AIMS OF THE STUDY
To assess quantitatively the severity and extent of coronary and carotid artery athero-
sclerosis and to correlate these measures to potential risk factors in a Finnish patient 
sample referred for clinically indicated coronary angiography.
The specifi c aims of the study were to:
1) Examine the relation between carotid IMT and angiographic severity and extent 
of CAD.
2) Defi ne the correlation between measures of coronary and carotid atherosclero-
sis and novel lipoprotein-related parameters such as PON1.
3) Investigate the association between measures of coronary and carotid athero-
sclerosis and remnants of TRLs in the postprandial state.
4) Discover the connection between measures of coronary and carotid atheroscle-
rosis and LDL oxidation parameters.
5) Elucidate the relation between measures of coronary and carotid atherosclerosis 
and measures of IR.
6) Scrutinize the link between measures of coronary and carotid atherosclerosis 
and apoE polymorphism.
A I M S  O F  T H E  S T U D Y
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4. SUBJECTS AND STUDY DESIGN
This cross-sectional study comprised 108 patients referred for elective coronary an-
giography at Helsinki University Central Hospital between March 1999 and De-
cember 2003. The study design included coronary angiography, ultrasound imaging 
of carotid arteries, extensive fasting blood samples, oral glucose tolerance test, and 
an oral fat-load test to be performed in each participant.
  To be eligible for the study, the participants had to be male or female 35 to 
75 years old with clinically suspected CAD (previous myocardial infarction and/or 
positive exercise test). The aims of these criteria were to include a representative, 
fairly unselected study sample and a wide range of atherosclerosis severity. Twenty-
four participants had type 2 DM, of whom 17 were treated with diet alone, two with 
metformin, three with sulfonylureas, and two with a combination of metformin and 
sulfonylureas. The mean duration of type 2 DM was 2.4 ±2.1 years. 
  The following exclusion criteria were applied: 1) patients referred primarily for 
evaluation of valvular or other structural heart disease, for arrhythmia evaluation, or 
consideration of heart transplantation, 2) previous coronary artery bypass grafting 
or percutaneous coronary intervention, 3) type 1 DM, 4) signifi cant renal failure 
(serum creatinine >150 µmol/L), and 5) physical, psychological, or logistic prob-
lems to participate in all protocol-defi ned procedures. One patient was excluded in 
studies II-V due to severe hypertriglyceridemia (TGs >14 mmol/L). 
  Written informed consent was obtained from all participants and the study de-
sign was approved by the institutional ethics committee. 
S U B J E C T S  A N D  S T U D Y  D E S I G N
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5. METHODS
5.1. Demographic variables
Study participants completed standard questionnaires to provide data on previous 
medical history, medication, smoking habits, and symptoms of CAD. Functional 
class was determined according to the classifi cation of the Canadian Cardiovascular 
Society (Campeau 1976). Presence of hypertension was defi ned as current use of 
antihypertensive drugs. Smoking status was recorded as those who smoked one or 
more cigarettes a day and those who had quit smoking or never smoked (studies 
I, III). The patients were also classifi ed as either nonsmokers or as past or present 
smokers (studies II, IV, V). Body mass index was calculated by dividing weight in 
kilograms by height in meters squared (kg/m²). The waist circumference was used 
as a measure of intra-abdominal fat deposition. 
5.2. Biochemical analyses
Blood samples were collected one month after coronary angiography after an over-
night fast. To avoid bias caused by medications, the patients were requested to ab-
stain from any lipid-lowering drugs between the time of angiography and blood 
sampling; only highly cardioselective β blockers (mainly bisoprolol) were permit-
ted. 
5.2.1. Lipid and lipoprotein measurements
Serum and ethylenediaminetetraacetic acid plasma were separated by centrifugation 
and stored at – 80°C until analyzed. Cholesterol and TG levels were measured by 
automated enzymatic procedures (Hoffman-La Roche, Basel, Switzerland). The 
LDL, HDL, HDL2, and HDL3 cholesterol levels were determined after separating 
the lipoprotein fractions from fresh fasting sera by sequential ultracentrifugation 
(Taskinen et al. 1988). Concentrations of apoA-I, apoA-II, apoB, and Lp(a) were 
measured by immunoturbidimetric methods with commercial kits (Boehringer-Man-
nheim, Mannheim, Germany). LpA-I-particles were quantifi ed using a differential 
electroimmunoassay (Sebia, Issy-les-Moulineaux, France) (Parra et al. 1990). The 
concentration of LpA-I/A-II-particles was calculated by subtracting the concentra-
tion of LpA-I from the total concentration of apoA-I in serum. LDL peak particle 
diameter (LDL particle size) was determined by a non-denaturing polyacrylamide 
gel electrophoresis (Vakkilainen et al. 2002a). A monoclonal antibody 4E6-based 
competition ELISA was used for measuring plasma levels oxLDL (Holvoet et al. 
2001). RLP-C was measured by an immunoseparation method using anti-human 
apoB-100 and anti-human apoA-1 monoclonal antibodies (Japan Immunoresearch 
Laboratories, Takasaki, Japan).
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  ApoE phenotyping was performed in serum by using the method of Havekes et 
al. (1987). ApoE concentration was determined using ELISA. Microtiter wells were 
coated with rabbit anti-human apoE IgG (R 107, rabbits were immunized with 
apoE purifi ed from human plasma). After sample incubation the bound apoE was 
detected with second antibody, horseradish peroxidase-conjugated rabbit anti-hu-
man apoE (DAKO A0077) (Siggins et al. 2003).
  PON-1 activity, using phenylacetate as substrate, was analyzed in serum samples 
as described previously (Blatter Garin et al. 1994, Blatter Garin et al. 1997). The se-
rum concentration of PON1 was assayed using a competitive ELISA (Blatter Garin 
et al. 1994).
5.2.2. Glucose and insulin measurements
All subjects underwent a 75-g standard oral glucose tolerance test, and blood 
specimen were collected before and 60, and 120 minutes after loading for de-
termination of plasma glucose and serum insulin concentrations. Fasting and 
post-load glucose were measured by the hexokinase method (Roche Diagnostic 
Gluco-quant) using either a Hitachi 917 or a Modular analyser (Hitachi Ltd, To-
kyo, Japan). Serum insulin concentrations were determined by double-antibody 
radioimmunoassay (Pharmacia RIA kit, Pharmacia, Uppsala, Sweden) after pre-
cipitation with polyethylene glycol. Abnormal glucose regulation was defi ned as 
a history of known DM or as a fasting plasma glucose ≥6.1 mmol/L or as 2-hour 
plasma glucose ≥7.8 mmol/L according to World Health Organization (WHO) 
criteria (1999). 
  To assess IR in the non-diabetic subjects, HOMA was calculated by using the fol-
lowing formula: HOMA IR = fasting insulin (mU/L) x fasting glucose (mmol/L)/
22.5 (Matthews et al. 1985).
5.2.3. Oral fat-load test and separation of TRL fractions
The study subjects consumed a high-fat meal comprising bread, butter, cheese, 
sliced sausage, boiled egg, paprika, soured whole milk, orange juice, and coffee. The 
energy content of this test meal was 65% fat, 20% carbohydrate, and 15% protein, 
and it was ingested within 10 minutes. The cholesterol intake was 490 mg. The fatty 
acid composition of the fat consumed was 65% saturated fat, 30% monounsaturated 
fat, and 5% polyunsaturated fat leading to a ratio of polyunsaturated fat to saturated 
fat of 0.08. Baseline blood samples were drawn before the meal after an overnight 
fast. Postprandial blood samples were obtained at 6 hours after the fatty meal.
  TRLs were isolated by density-gradient ultracentrifugation (Syvänne et al. 1993). 
The following lipoprotein fractions were separated: the Sf>400 fraction represent-
ing CMs and large VLDLs, and the Sf 12-400 fraction corresponding to the typical 
VLDL and IDL density in fasting plasma. Concentrations of apoB-48 and apoB-100 
were analyzed from TRL fractions (Mero et al. 2000).
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5.3. Ultrasonographic measurement of carotid IMT
B-mode ultrasound imaging was performed with a Hewlett-Packard Image point 
M2410A ultrasound system (Hewlett-Packard, Andover, USA) equipped with a 10 
MHz linear array transducer and videotaped with a Panasonic AG-MD830E PAL 
S-VHS VCR. All examinations were carried out by the same operator, who was 
blinded to the quantitative coronary angiographic results. Subjects were examined 
in the supine position. Longitudinal images from three angles of interrogation (an-
terolateral, lateral, and posterolateral) were displayed bilaterally for the common 
carotid artery, carotid bifurcation, and internal carotid artery. Measurements were 
carried out at a total of 28 sites per patient from three projections for both the FW 
and the NW of the common carotid artery and carotid bifurcation, and the one 
best visualized projection for internal carotid artery. The images were frozen in the 
diastole, assessed as the phase when lumen diameter is at its smallest and IMT at its 
largest. 
  Computer analysis of ultrasound images was performed by a single reader at the 
Research Institute of Public Health, Kuopio, Finland. The reader´s repeatability has 
been assessed earlier in another study with an identical carotid ultrasound protocol 
(Ylitalo et al. 2002). IMT measurements from videotapes were made at a total of 28 
sites corresponding to the 28 sites where the scanning was focused. The mean, maxi-
mum, and minimum IMT were derived from each measurement. For each subject 
the mean IMT was calculated as the average of all mean IMT measurements over 28 
sites. Likewise, maximum IMT was calculated as the average of the thickest points 
recorded in each segment. 
5.4. Coronary angiography
Coronary angiography was performed by the percutaneous femoral approach using 
standard angiographic techniques. The left and right coronary arteries were imaged in 
multiple projections to permit an adequate diagnostic study as well as a quantitative 
analysis. Sublingual nitroglycerin was routinely administered to control vasomotor 
tone. 
5.4.1. Visual analysis of coronary angiograms
Angiographic scoring was performed by interventional cardiologists who were 
blinded to the study protocol. Mild CAD on visual interpretation was defi ned as lu-
men diameter reduction <50%, and signifi cant CAD as the presence of any luminal 
stenosis ≥50%. Due to the fact that most therapeutic decisions are based on visual 
angiographic results in clinical practice, patients in publications I and II were divided 
into two subgroups such that those without any or with mild CAD comprised one 
group and those with ≥1 signifi cantly affected coronary artery the other.
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5.4.2. Frame selection for quantitative coronary angiography 
analysis
Coronary segments were analyzed in one angiographic view. The frames for QCA 
analysis were selected by one of the investigators using the following criteria: mini-
mal foreshortening and overlap, good visualization of any stenoses within the seg-
ment, and optimal contrast and image quality available. Usually the selected frames 
were in end-diastole or in the diastasis period. 
5.4.3. Segmental classifi cation of the coronary tree
Classifi cation of the coronary tree is illustrated in Figure 7. The coronary segments 
were classifi ed into four categories based on their location. The left main coronary 
artery was analyzed separately. Proximal parts of the anterior descending, the left 
circumfl ex, and the right coronary arteries were considered proximal segments. Mid 
segments comprised the mid parts of the three main coronary arteries. All segments 
distal to the mid segments were regarded as distal segments. The distal segments 
included also the fi rst and the second diagonal and obtuse marginal branches when-
ever these arteries were considered suitable for analysis by QCA. In addition, if large 
and well visible, we included the posterolateral branches of the left circumfl ex artery 
and the right coronary artery, the right ventricular branch and the acute marginal 
branch among the distal segments. Segments with a diameter of approximately ≤1.5 
mm were excluded from analysis. 
Figure 7. Segmental classifi cation of the coronary tree. LCA, left main coronary artery; 
LAD, left anterior descending coronary artery; LD1, LD2, left diagonal branches; LCX, 
left circumfl ex coronary artery; LOM1, LOM2, left obtuse marginal branches; RCA, 
right coronary artery; RV, right ventricular branch; RAM, right acute marginal branch; 
RPL, right posterolateral branch; RIVP, right interventricular posterior branch.
54 M E T H O D S
5.4.4. Qantitative analysis of coronary angiograms
The coronary angiograms were analyzed using third-generation QCA software, the 
Cardiovascular Measurement System (QCA-CMS) version 3.0 (Medis, Nuenen, the 
Netherlands). This system has been described elsewhere in detail (Reiber et al. 1993) 
and has also been validated in our laboratory (Syvänne et al. 1994b, Pajunen et al. 
1997). All QCA analyses were carried out by one of the investigators. The contrast-
fi lled catheter lumen diameter was used as a calibration standard. A stenosis was con-
sidered to be present when the fi rst analysis indicated a diameter narrowing of at 
least 20% (Syvänne et al. 1994b). An example of a quantitative analysis result page is 
presented in Figure 5.
5.4.5. Measures of severity, extent, and atheroma burden of CAD
Based on computer-aided analysis, we assessed the severity, extent, and overall 
atheroma burden indexes to describe per-patient characteristics of CAD (Figure 8). 
These three indexes were calculated for the entire coronary tree of each patient (glo-
bal) and separately for the proximal, mid, and distal segments.
  Severity: Severity refers to the tightest diameter stenosis within a certain coro-
nary territory. It was defi ned as the narrowest lesion expressed in percentage diameter 
stenosis (ranging from zero if no stenosis was present to 100% in case of a total oc-
clusion) in the left main, left anterior descending, left circumfl ex, and right coronary 
artery territory. The global PDS index was counted as the average of the most severe 
stenoses in these four vessels. The severity index was likewise calculated for proximal-, 
mid-, and distal segments of the coronary tree.
  Extent: Extent was defi ned as the percentage of a coronary segment involved in 
a stenosis and was calculated as: 100 x stenosis length/segment length. If a segment 
contained >1 stenosis, the sum of the stenosis lengths was used. The extent indexes 
(global, left main, proximal, mid, distal) were calculated as sums of the pertinent 
stenosis length values divided by total length of segments available for analysis.
  Atheroma burden:  Atheroma burden was derived from the plaque area (ex-
pressed in square millimeters), which represents a two-dimensional projection of the 
area covered by atherosclerotic tissue within the stenosis. The sum of the QCA-de-
rived plaque areas within a certain segment were divided by the respective segment 
lengths, and the global atheroma burden index was the sum of all the plaque areas 
measured divided by total length of all the segments available for analysis.
  Total occlusions: To avoid excluding data on the most severely diseased vessels, 
extent and plaque areas of totally occluded segments were imputed as follows. For 
any occluded segment (e.g. proximal left anterior descending artery), the maximum 
stenosis length or plaque area measured in the corresponding segment of any pa-
tient was taken to represent the pertinent value for that segment. The denominator 
needed to calculate the extent and atheroma burden values was the length of the 
most severely diseased corresponding segment; however this was adjusted for the 
average lengths of those segments within the study group. 
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5.6. Statistical analyses
All statistical analyses were performed with SPSS 11.5 for Windows (SPSS Inc., 
Chicago, IL, USA). Data are presented as frequencies or percentages for categorical 
variables and as mean ± standard deviation for continuous variables, unless otherwise 
noted. Normality of continuous variables was checked by the Kolmogorov-Smirnov 
test. Logarithmic tranformation of variable was done, if necessary. Correlations were 
calculated by the univariate Spearman correlation coeffi cients. Between-group dif-
ferences were assessed by the Mann-Whitney U-test, the Kruskal-Wallis test, one-
way analysis of variance, and the chi-square test, as appropriate.
  Friedmans test (study I) was used to compare the severity and extent of CAD 
between proximal, mid, and distal vessel segments. Wilcoxons signed rank test was 
used (study III) to compare postprandial with fasting values. The means of continu-
ous variables between different study groups (studies IV and V) were compared by 
using the analysis of covariance with adjustment for age and gender. 
  Multivariate linear regression analyses were employed to assess the predictors of 
global PDS index (studies I, II, and IV) or global atheroma burden index (studies 
III and V). To adjust for confounding, age and sex were included in all multivariate 
regression models. P values <0.05 were considered signifi cant.
Figure 8. Schematic diagram of a coronary segment illustrating defi nitions of the angi-
ographic indexes. The vessel (reference) diameter is 2.5 mm. The lesion on the left has 
a minimum luminal diameter (MLD) of 0.50 mm, and therefore a percent diameter 
stenosis (PDS) (measure of severity) of 80 %. The length of the lesion is 2.0 mm. The 
lesion on the right is less severe but longer. Segment length is 10 mm; thus extent in 
this segment is 100 x (2 + 4 mm)/10 mm = 60%. ”Plaque areas” defi ning ”atheroma 
burden” are shown in black. 
Adapted with permission from Pia Pajunen, Doctoral Thesis 2002.
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6. RESULTS
6.1. Association between coronary and carotid 
atherosclerosis (Study I)
6.1.1. Study population
The demographic and clinical characteristics of the study population are presented 
in Table 3. Typical atherosclerotic risk factors and symptoms of CAD were preva-
lent. Most patients had evidence of ischemia during exercise testing, and 39 (36%) 
patients had suffered a previous myocardial infarction. A high percentage of partici-
pants was taking aspirin, β blockers, and lipid-lowering drugs at baseline.
Table 3. Demographic and clinical characteristics of the study population (n=108).
Variable Median (interquartile ranges)or frequencies (%)
Age (years) 61 (55-65)
Male/Female 81/27 (75%/25%)
Body mass index (kg/m²) 27.2 (25.0-29.0)
Total cholesterol (mmol/L) 5.57 (4.72-6.50)
HDL cholesterol (mmol/L) 1.31 (1.13-1.50)
LDL cholesterol (mmol/L) 3.37 (2.75-4.17)
Triglycerides (mmol/L) 1.77 (1.32-2.42)
Fasting plasma glucose (mmol/L) 5.5 (5.1-6.3)
2-hour plasma glucose (mmol/L) 6.8 (5.4-8.9)
Current smoker 18 (17%)
Hypertension 63 (58%)
Abnormal glucose regulation 44 (41%)
Previous myocardial infarction 39 (36%)
Previous cerebrovascular disease 4 (4%)
Positive exercise test 85 (79%)
Canadian Cardiovascular Society class 
 I 7 (6%)
         II 46 (43%)
 III 50 (46%)
         IV 5 (5%)
Medication use
Aspirin 100 (93%)
β blocker 91 (84%)
Statin 77 (71%)
Angiotensin-converting enzyme inhibitor 31 (29%)
Calcium channel blocker 21 (19%)
Diuretics 14 (13%)
Long-acting nitrates 50 (46%)
Later treatment of CAD
Medical 37 (34%)
Percutaneous coronary intervention 44 (41%)
CABG 27 (25%)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; CAD, coronary artery disease; CABG, 
coronary artery bypass grafting.
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6.1.2. Visual angiographic and quantitative coronary 
angiographic results
On visual interpretation only 11 (10%) subjects had normal coronary arteries. Mild 
CAD was diagnosed in 12 participants (11%), one-vessel CAD in 28 (26%), two-
vessel CAD in 27 (25%), and three-vessel CAD in 30 (28%). Fourteen subjects had 
signifi cant CAD in the left main coronary artery.
  The global PDS index was 30.9±13.6 (range 0 to 60.4), the global extent index 
was 14.0±6.8 (range 0 to 31.3), and the global atheroma burden index was 7.5±4.8 
(range 0 to 23.2). PDS indexes were 14.6±13.2 (range 0 to 62.3) for proximal 
segments, 20.7±16.9 (range 0 to 77.4) for mid segments, and 19.3±12.1 (range 0 
to 53.6) for distal segments. Extent indexes were 15.2±12.9 (range 0 to 46.1) for 
proximal segments, 17.0±13.0 (range 0 to 46.7) for mid segments, and 13.0±7.5 
(range 0 to 42.6) for distal segments. Atheroma burden indexes were 10.2±11.1 
(range 0 to 54.9) for proximal segments, 10.8±11.1 (range 0 to 45.3) for mid seg-
ments, and 5.9±4.4 (range 0 to 20.6) for distal segments. PDS index was lower in 
the proximal segment than in the mid and distal segments (p=0.003). We found, 
however, no signifi cant differences between the types of vessel segment if the extent 
or the atheroma burden index was used (p=0.269 and p=0.116, respectively).
6.1.3. Relation between carotid IMT and severity and extent of 
CAD
In univariate analyses, maximum IMT values were signifi cantly associated with 
the QCA-derived global indexes for the severity, extent, and atheroma burden of 
CAD (Figure 9 A-C). We found higher maximum IMT values (1.35±0.23 versus 
1.20±0.20 mm, p=0.013) in the group with signifi cant CAD as compared with 
those with no or mild CAD. The result was similar when mean instead of maximum 
IMT value was used (1.07±0.19 versus 0.95±0.16 mm, p=0.013). Further, means 
of maximum IMT were 1.20±0.20 mm in mild CAD, 1.27±0.22 mm in one-vessel 
CAD, 1.40±0.22 mm in two-vessel CAD, and 1.40±0.24 mm in three-vessel CAD 
(p=0.005). The outcome was essentially comparable when mean of mean instead of 
mean of maximum IMT was used.
  Interestingly, we found heterogeneity in associations between IMT and CAD 
indexes according to anatomical location of CAD. Maximum and mean IMT values, 
respectively, were correlated with quantitative angiographic indexes for mid and dis-
tal segments only and not for left main coronary artery or proximal segments.
  Analysis based on quartiles of the distributions of maximum and mean IMTs, re-
spectively, suggested a non-linear relationship with global CAD severity so that only 
the lowest IMT values were related to mild CAD (Figure 10 A-B). Global extent 
and atheroma burden indexes showed similar associations (data not shown). 
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Figure 9 A-C. Correlations among maximum IMT (n=97) and global percent diameter 
stenosis (PDS) index (A), global extent index (B), and global atheroma burden index 
(C). For defi nition of the indexes, see text (chapter 5.4.5.).
Reprinted from the original publication (I) with the permission from the publisher 
(Elsevier).
  In multivariate analysis only smoking (p<0.001), and to a lesser degree, age 
(p=0.084) were signifi cant predictors of the global PDS index, whereas hyperten-
sion, total cholesterol, and abnormal glucose regulation were not. The model ac-
counted for 14.2% of the variation of the global PDS index. When the variable maxi-
mum IMT was added, the accountability of the model increased by 5.9 percentage 
points. Not surprisingly, the addition of gender, further increased the predictive 
power of the model, but maximum IMT no longer retained its independent predic-
tive power, presumably because of an overriding infl uence of sex in the model. In 
contrast, there was no evidence of interaction between maximum IMT and gender 
terms in a further analysis with global PDS index as the dependent variable, suggest-
ing that the relation between IMT and CAD severity is similar in men and women.
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Figure 10 A-B. Relation between global percent diameter stenosis (PDS) index by 
maximum IMT quartile (A) and mean IMT quartile (B). Values of global PDS index are 
presented as mean ±SEM. For defi nition of the index, see text (chapter 5.4.5).
Reprinted from the original publication (I) with the permission from the publisher (El-
sevier).
6.2. PON-1 activity and concentration and coronary and 
carotid atherosclerosis (Study II)
6.2.1. PON1 activity and concentration and clinical and lipid 
variables
In univariate correlation analyses PON1 activity and concentration were signifi -
cantly correlated with HDL cholesterol (p=0.005 for both), apoA-I (p<0.001 and 
p=0.006, respectively), apoA-II (p<0.001 for both), and LpAI-/A-II (p=0.001 and 
p=0.016 respectively). The HDL3 cholesterol level was associated with borderline 
signifi cance to PON1 activity and concentration (p=0.050 and p=0.065, respec-
tively). In addition, PON1 activity was associated with gender (p=0.035), abnormal 
glucose regulation (p=0.045), and LpA-I (p=0.013) (Table 4). 
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Table 4. Correlation coeffi cients between PON1 activity and concentration and 
selected variables.
 PON1 activity            PON1 concentration
 (U/mL)               (ug/mL)
  r p r p
Age (years) -0.150 0.123 -0.132 0.175
Gender 0.204 0.035 0.184 0.058
Hypertension -0.100 0.307 -0.165 0.088
Current or former smoker -0.112 0.250 -0.143 0.142
Abnormal glucose regulation -0.194 0.045 -0.115 0.237
Total cholesterol 0.075 0.444 0.161 0.097
HDL cholesterol 0.268 0.005 0.270 0.005
HDL2 cholesterol 0.150 0.124 0.170 0.080
HDL3 cholesterol 0.190 0.050 0.179 0.065
LDL cholesterol -0.034 0.728 0.044 0.653
VLDL cholesterol 0.049 0.618 0.056 0.565
Triglycerides 0.084 0.387 0.107 0.272
ApoA-I 0.355 <0.001 0.263 0.006
ApoA-II 0.368 <0.001 0.386 <0.001
ApoB -0.034 0.725 0.080 0.412
LpA-I 0.240 0.013 0.178 0.067
LpA-I/A-II 0.304 0.001 0.232 0.016
Global PDS index -0.364 <0.001 -0.306 0.001
Global extent index -0.221 0.022 -0.161 0.097
Global atheroma burden index -0.277 0.004 -0.229 0.017
Mean carotid IMT 0.018 0.860 -0.094 0.360
Maximum carotid IMT 0.008 0.939 -0.107 0.298
PON1, paraoxonase-1; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-
density lipoprotein; ApoA, apolipoprotein A; ApoB, apolipoprotein B; LpA, lipoprotein A; PDS, percent 
diameter stenosis; IMT, intima-media thickness.
6.2.2. PON1 activity and concentration, severity and extent of 
CAD, and carotid IMT
As outlined in Table 4, PON1 activity was signifi cantly and inversely associated 
with the QCA-derived global indexes for the severity (p<0.001), extent (p=0.022), 
and global atheroma burden (p=0.004). Similarly, PON1 concentration correlated 
signifi cantly with global PDS index (p=0.001) and global atheroma burden index 
(p=0.017). Neither PON1 activity nor concentration was associated with carotid 
IMT.
  We found lower values of PON1 activity (84±2 versus 100±5 U/mL, p=0.003) 
and PON1 concentration (94±3 versus 110±6 ug/mL, p=0.016), respectively, in the 
group with signifi cant CAD as compared with the group with no or mild CAD.
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  Furthermore, mean values of QCA-derived global indexes for the severity, ex-
tent, and atheroma burden of CAD decreased in a stepwise manner across the ter-
tiles of PON1 activity (Figure 11 A-C). Similar associations were found when tertiles 
of PON1 concentration instead of tertiles of PON1 activity were used (data not 
shown). 
  To establish independent determinants of global PDS index, we performed a 
linear regression analysis controlled for age, gender, hypertension, abnormal glucose 
regulation, smoking status, HDL cholesterol, and PON1 activity. In the fi nal model 
that explained 25.1% of variation of global PDS index, the most important deter-
minants were gender (p=0.001) and PON1 activity (p=0.016). The outcome was 
similar when replacing HDL cholesterol with HDL2 cholesterol, HDL3 cholesterol, 
apoA-I, or apoA-II (data not shown). 
Figure 11 A-C. Relationship between paraoxonase-1 (PON1) activity tertile by global 
percent diameter stenosis (PDS) index (A), global extent index (B), and global atheroma 
burden index (C), respectively. For defi nition of the indexes, see text (chapter 5.4.5.).
Reprinted from the original publication (II) with the permission from the publisher 
(Elsevier).
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6.3. Postprandial lipemia (Study III)
6.3.1 Postprandial responses of plasma TGs and TRLs 
The level of plasma TGs was signifi cantly increased at 6 hours after intake of oral fat 
meal as compared to fasting value (2.96±0.13 versus 2.23±1.12 mmol/L, p<0.001). 
Similarly the concentration of TGs in CM + large VLDL (Sf>400) and in VLDL + 
IDL (Sf 12-400) fractions increased postprandially (0.35±0.03 versus 0.10±0.02 
mmol/L and 1.70±0.09 versus 1.32±0.09 mmol/L, respectively, p<0.001 for both).
The apoB-48 concentration also increased at 6 hours in CM + large VLDL (Sf>400) 
and especially in VLDL + IDL (Sf 12-400) fractions compared to fasting values 
(0.21±0.02 versus 0.05±0.01 mg/L and 14.95±1.11 versus 8.86±0.80 mg/L, re-
spectively, p<0.001 for both). Likewise, the apoB-100 concentration rose postpran-
dially in CM + large VLDL (Sf>400) and in VLDL + IDL (Sf 12-400) fractions 
(0.49±0.06 versus 0.33±0.05 mg/L, p<0.001 and 661±44 versus 624±42 mg/L, 
p<0.05, respectively).
6.3.2. Postprandial responses of RLP-C, oxLDL, and LDL 
particle size
The concentration of RLP-C was elevated 6 hours after oral fat meal as compared 
to baseline value (13.73±1.08 versus 10.16±0.90 mmol/L, p<0.001). OxLDL was 
also markedly increased 6 hours postprandially (104±2 versus 92±3 U/L, p<0.001). 
The mean peak particle size of LDL remained unchanged 6 hours after test meal 
(25.1±0.1 versus 25.1±0.1 nm, p=0.099).
6.3.3. Correlations between postprandial lipoproteins and other 
selected variables
A strong correlation existed between RLP-C and total TGs in fasting and in fed 
state (Figure 12 A-B). Likewise, the postprandial RLP-C correlated with respective 
TGs in Sf>400 (r=0.737, p<0.001) and Sf 12-400 (r=0.857, p<0.001), apoB-48 in 
Sf>400 (r=0.710, p<0.001) and Sf 12-400 (r=0.664, p<0.001), apoB-100 in Sf > 
400 (r=0.812, p<0.001) and Sf 12-400 (r=0.533, p<0.001). 
  Interestingly, RLP-C correlated with oxLDL both in fasting and in fed state 
(Figure 13 A-B). There was an inverse relationship between RLP-C and LDL parti-
cle size before and 6 hours after oral fat load (Figure 14 A-B).
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Figure 13 A-B. Correlations among the cholesterol content of remnant lipoprotein 
particles (RLP-C) and oxidized LDL (oxLDL) in fasting (A) and in fed (B) state.
Figure 12 A-B. Correlations among the cholesterol content of remnant lipoprotein 
particles (RLP-C) and total triglycerides (TGs) in fasting (A) and in fed (B) state.
Figure 14 A-B. Correlations among the cholesterol content of remnant lipoprotein 
particles (RLP-C) and LDL particle size in fasting (A) and in fed (B) state. 
64 R E S U L T S
6.3.4. Correlation between postprandial lipemia, severity and 
extent of CAD, and carotid IMT 
The concentration of TGs in plasma in Sf>400 or in Sf 12-400 lipoprotein fractions 
was neither correlated with carotid IMT nor severity and extent of coronary athero-
sclerosis at 6 hours after oral fat intake or at baseline. Fasting or postprandial values 
of apoB-48 and apoB-100 in Sf >400 or in Sf 12-400 lipid fractions had no signifi -
cant association with coronary or carotid atherosclerosis, except the concentration 
of apoB-48 in Sf 12-400 fraction, which had a weak positive relationship with global 
atheroma burden index (r=0.241, p<0.05). 
6.3.5. OxLDL, severity and extent of CAD, and carotid IMT
In univariate analysis the concentration of oxLDL in either fasting or in postprandial 
state did not correlate with global atheroma burden index or carotid IMT. 
  In multivariate analyses, however, oxLDL was a determinant of global atheroma 
burden index at postprandial state but not at fasting state (p=0.042 versus p=0.382, 
respectively). In addition, age (p=0.018), female gender (p=0.002), current smok-
ing (p=0.018), and to a lesser degree abnormal glucose regulation (p=0.092), were 
predictors of global atheroma burden index. Hypertension, total TG levels, and 
LDL and HDL cholesterols did not reach signifi cance in the models.
  Furthermore, as indicated above, in univariate analysis, TGs showed a strong 
relationship with RLP-C both in the fasting and in the fed state. Consequently, these 
variables were not forced into the same model. The results in multivariate regression 
analyses were, however, similar when replacing TGs with RLP-C. 
6.4. Insulin resistance and coronary and carotid 
atherosclerosis (Study IV)
6.4.1. IR, biochemical variables, and carotid IMT
The study subjects were categorized into three groups. Non-diabetic subjects were 
divided into group 1 (n=41) with HOMA IR <1.8 (the median value) and group 2 
(n=42) with HOMA IR ≥1.8. Diabetic subjects comprised group 3 (n=24). 
  Clinical, biochemical, and other study variables of the study groups are pre-
sented in Table 5. Patients in groups 2 and 3 had higher body mass index, waist cir-
cumference, and were more likely to be hypertensive compared with group 1. Total 
cholesterol, LDL cholesterol, and apoB levels were similar among the three groups. 
Subjects in groups 2 and 3 had lower HDL cholesterol and apoA-I levels than subjects 
in group 1. The TGs did not differ signifi cantly between the groups. LDL particle 
size was smaller in the group 3 compared with group 1. Carotid IMT did not reach 
statistical signifi cance across the study groups. 
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Age (years) 60 (56-64) 63 (55-65) 58 (52-66) 0.591
Male/Female 25/16 (61/39) 35/7 (83/17) 20/4 (83/17) 0.035
Body mass index (kg/m2) 25.7 (23.6-27.4) 27.9 (25.7-30.0) 28.3 (27.2-31.6) <0.001
Waist cirumference (cm) 98±10 105±11 108±9 <0.001
Current or former smoker 19 (46) 27 (64) 14 (58) 0.250
Hypertension 16 (39) 28 (67) 18 (75) 0.006
Previous myocardial infarction 13 (32) 18 (43) 7 (29) 0.434
Previous cerebrovascular disease 1 (2) 3 (7) 0 (0) 0.290
Total cholesterol (mmol/L) 5.74±1.18 5.66±1.27 5.48±1.43 0.728
HDL cholesterol (mmol/L) 1.45±0.32 1.28±0.25 1.22±0.27 0.003
LDL cholesterol (mmol/L) 3.58±1.00 3.57±0.99 3.11±0.89 0.128
Triglycerides (mmol/L) 1.66 (1.23-2.20) 1.99 (1.44-2.36) 1.82 (1.44-3.76) 0.058
LDL particle size (nm) 26.0 (25.6-26.5) 25.5 (24.4-26.3) 24.7 (24.0-26.4) 0.026
ApoA-I (mmol/L) 3.70 (3.26-4.18) 3.24 (3.03-3.82) 3.31 (2.87-3.83) 0.016
ApoA-II (mmol/L) 0.93 (0.84-1.11) 0.93 (0.81-1.14) 0.84 (0.72-1.01) 0.070
ApoB (mmol/L) 3.02±0.74 3.28±0.84 3.28±1.05 0.406
LpA-I (mmol/L) 1.37±0.44 1.22±0.37 1.24±0.26 0.237
LpA-I/A-II (mmol/L) 2.38±0.50 2.20±0.43 2.04±0.45 0.018
Fasting plasma glucose (mmol/L) 5.2 (4.9-5.6) 5.4 (5.2-5.7) 7.1 (6.5-7.9) <0.001
1-hour plasma glucose (mmol/L) 8.2 (6.0-10.4) 9.2 (7.3-10.1) 12.7 (11.1-15.6) <0.001
2-hour plasma glucose (mmol/L) 6.1 (5.1-7.4) 6.6 (4.9-7.9) 11.8 (7.8-15.1) <0.001
Fasting plasma insulin (mU/L) 4.9 (4.2-6.4) 9.8 (8.3-15.6) 11.9 (6.6-20.9) <0.001
1-hour plasma insulin (mU/L) 46.7 (28.4-61.4) 64.5 (49.9-109.4) 58.2 (42.1-85.9) 0.001
2-hour plasma insulin (mU/L) 35.8 (25.1-43.7) 52.5 (33.6-84.1) 55.4 (27.8-98.1) 0.004
Mean IMT (mm) 1.00±0.18 1.07±0.18 1.07±0.20 0.198
Maximum IMT (mm) 1.26±0.22 1.35±0.22 1.36±0.26 0.156
Data are presented as means ±SD, medians (interquartile ranges), or as frequencies (%). 
*p-values from analysis of variance (means of continuous variables) across the three groups. 
HOMA IR, the homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; ApoA, apolipoprotein A; ApoB, apolipoprotein B; LpA, lipoprotein A; IMT, 
intima-media thickness. 
6.4.2. IR and severity and extent of CAD
The age- and gender-adjusted QCA-derived global indexes for the severity, extent, 
and overall atheroma burden of CAD were signifi cantly higher in the group 2 than 
in group 1. Similarly, the global severity, global extent, and global atheroma burden 
indexes were higher in the group 3 compared with group 1 (Table 6).
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  We found heterogeneity in associations between IR and CAD indexes according 
to anatomical location of CAD. Compared with group 1, individuals in the group 
2 had more severe and extensive CAD in distal segments only, but not in the left 
main coronary artery, proximal, or mid coronary segments. Similar results were seen 
when group 3 was compared with group 1 (Table 6).
  Factors independently correlated with global PDS index in multivariate analysis 
were gender (p=0.002), HOMA IR group (p=0.010), and to a lesser degree waist 
circumference (p=0.059). Together, these factors explained 29.7% of the severity of 
CAD. Age, hypertension, smoking status, TGs, and HDL and LDL cholesterols did 
not reach statistical signifi cance in this model. 
















PDS 24±14 35±11 0.007 35±13 0.027
Extent 11±7 15±5 0.038 16±8 0.090
Atheroma burden 6±4 8±4 0.035 9±6 0.024
PDS index
Left main coronary 
artery
0±3 2±7 0.680 4±14 0.123
Proximal segment 12±14 16±12 0.391 15±13 0.587
Mid segment 16±18 23±14 0.227 22±16 0.519
Distal segment 14±10 21±10 0.016 25±14 0.002
Extent index
Left main coronary 
artery
0±4 2±10 0.586 6±19 0.147
Proximal segment 13±14 16±12 0.596 16±12 0.495
Mid segment 13±14 20±11 0.085 17±14 0.545
Distal segment 10±7 14±6 0.037 16±9 0.026
Atheroma burden index
Left main coronary 
artery
0±1 1±7 0.424 5±22 0.160
Proximal segment 7±8 11±9 0.307 12±14 0.157
Mid segment 8±10 12±10 0.128 12±13 0.362
Distal segment 4±4 6±4 0.125 7±5 0.048
Values are expressed as means ±SD. 
*p-values are presented for analysis of covariance between groups 1 and 2 with adjustment for age and gender.
†p-values are presented for analysis of covariance between groups 1 and 3 with adjustment for age and gender. 
HOMA IR, the homeostasis model assessment of insulin resistance; PDS, percent diameter stenosis. 
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6.5. Apolipoprotein E polymorphism and coronary and 
carotid atherosclerosis (Study V)
6.5.1. ApoE phenotype and biochemical variables
Based on apoE phenotype distribution the study population was divided into two 
groups; those with apoE3/E3 phenotype (n=51), (apoE3 group), and those with 
either apoE4/E3 or E4/E4 (n=40), (apoE4 group). Subjects with the phenotypes 
apoE2/E3 (n=3) and apoE4/E2 (n=2) were excluded from further analysis. 
  Table 7 shows clinical and biochemical characteristics of all 91 patients by apoE 
phenotype groups. Total cholesterol and HDL and LDL cholesterols did not dif-
fer among the apoE phenotype groups. ApoE4 subjects had higher levels of TGs, 
RLP-C, apoB, LpA-I/A-II, and Lp(a). The mean LDL particle size was smaller in 
the apoE4 group than in the apoE3 group. There was no difference in the mean 
concentration of apoE between the study groups.







Age (years) 61.2±1.0 58.1±1.1 0.032
Male/female 36/15 (71/29) 29/11 (72/28) 0.841
Body mass index (kg/m²) 27.3±0.4 27.8±0.6 0.801
Current or former smoker 29 (57) 23 (58) 0.951
Hypertension 30 (59) 22 (55) 0.715
Abnormal glucose regulation 17 (33) 17 (42) 0.370
Previous myocardial infarction 21 (41) 10 (25) 0.106
Previous cerebrovascular disease 1 (2) 3 (8) 0.201
Total cholesterol (mmol/L) 5.54±0.17 5.96±0.20 0.125
Triglycerides (mmol/L) 1.78±0.11 2.54±0.24 0.006
LDL cholesterol (mmol/L) 3.49±0.13 3.62±0.17 0.680
HDL cholesterol (mmol/L) 1.35±0.04 1.35±0.05 0.789
HDL2 cholesterol (mmol/L) 0.54±0.04 0.54±0.04 0.804
HDL3 cholesterol (mmol/L) 0.81±0.03 0.81±0.03 0.924
ApoA-I (mg/dL) 134±3 139±4 0.388
ApoA-II (mg/dL) 36±1 37±1 0.215
ApoB (mg/dL) 115±4 135±6 0.008
LpA-I (mg/dL) 51±2 48±2 0.329
LpA-I/A-II (mg/dL) 83±2 92±3 0.030
Lp(a) (mg/dL) 189±22 270±31 0.041
LDL particle size (nm) 25.8±0.2 25.2±0.2 0.041
Fasting RLP-C (mg/dL) 7.83±0.49 12.68±1.92 0.023
ApoE (µg/mL) 37.5±1.7 35.1±2.3 0.370
Values are given as means ±SEM or frequencies (%).
*p-values are presented for Mann-Whitney U-test (continuous variables) or the chi-square test
(categorical variables). 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoA, apolipoprotein A; ApoB,
apolipoprotein B; ApoE, apolipoprotein E; LpA, lipoprotein A; RLP-C, the cholesterol content of remnant 
lipoprotein particle. 
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6.5.2. ApoE phenotype, severity and extent of CAD,
and carotid IMT
As outlined in Table 8 maximum and mean IMT were higher in the apoE4 group than 
in the apoE3 group even after adjustment for age and gender. Likewise, the global 
atheroma burden index was higher in the apoE4 group than in the apoE3 group. 
Table 8. Carotid IMT and severity and extent of CAD by apoE phenotype groups.
Variable E3 E4 p*
 (n=51) (n=40) 
Mean IMT (mm) 1.02±0.03 1.07±0.03 0.027
Maximum IMT (mm) 1.29±0.03 1.37±0.03 0.022
Global atheroma burden index 6.60±0.63 8.26±0.73 0.033
Data are presented as means ±SEM. 
*p-values are presented for analysis of covariance between apoE phenotype groups with adjustment for age 
and gender. 
IMT, intima-media thickness. 
  The multivariate regression analyses revealed that, age (p=0.001), gender 
(p=0.001), apoE4 group (p=0.028), and to a lesser degree, smoking (p=0.075), and 
hypertension (p=0.091) were signifi cant predictors of maximum IMT. ApoB, LpA-
I/A-II, LDL particle size, and abnormal glucose regulation were also included in the 
model, but they did not reach individual signifi cance. The model accounted for 26.6% 
of the variation of maximum IMT. However, when Lp(a) was added in this model, 
the impact of apoE4 group was of borderline signifi cance (p=0.060). When only age, 
gender, and Lp(a) were introduced in the multivariate regression model, Lp(a) was a 
signifi cant determinant of mean IMT (p=0.012). The results were essentially compa-
rable when mean IMT instead of maximum IMT was used as dependent variable.
  Gender (p=0.001) and apoE4 group (p=0.037) were the main determinants that 
explained 19.4% of variation of global atheroma burden index. When adding Lp(a) 
in this model, as well, apoE4 group was still related with borderline signifi cance to 
the global atheroma burden index (p=0.063).  
  In bivariate correlation analysis apoB was correlated with TGs (r=0.683, 
p<0.0001) and LDL cholesterol (r=0.608, p<0.0001), respectively. TGs showed a 
strong relationship with fasting RLP-C levels (r=0.814, p<0.0001). Therefore these 
variables were not forced into the same model. The results in multivariate regression 
analyses were, however, similar when replacing apoB with TGs, LDL cholesterol, or 
RLP-C levels (data not shown).
  Further, in bivariate correlation analysis, the concentration of apoE was not re-
lated to global atheroma burden index, maximum or mean IMT neither in apoE3 
group nor in apoE4 group (data not shown). The absence of an association of the 
apoE concentration with coronary or carotid atherosclerosis was also seen in multi-
variate regression analysis (data not shown).
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7. DISCUSSION
7.1. General view
This thesis includes a representative sample of 108 previously non-intervened pa-
tients, who underwent elective coronary angiography for clinical suspicion of CAD at 
the Helsinki University Central Hospital. A wide array of disease severity was repre-
sented, ranging from angiographically normal coronaries to widespread CAD requir-
ing bypass surgery.
  The majority of our patients had several risk factors for CAD, symptoms that 
suggested angina of functional class II or more, and a positive exercise test result. 
In addition, a large percentage of participants was taking aspirin, β blockers, and 
lipid-lowering drugs at baseline. These factors and the relatively small sample size 
may have overshadowed the relationships between cardiovascular risk factors and the 
severity and extent of coronary and carotid artery atherosclerosis. 
  The lack of a control group should be mentioned. However, inclusion of a refer-
ence population free from CAD would be unethical, because of the invasive nature 
of the methods utilized in our study. Furthermore, this study has by nature a cross-
sectional design; thus, it is not possible to draw defi nite conclusions regarding inde-
pendent risk factors for CAD. A follow-up study is required for such conclusions. 
7.2. Methodological aspects
7.2.1. Quantitative coronary angiography
Computer-based analysis of coronary angiograms was used for measuring the sever-
ity and extent of coronary atherosclerosis. Invasive coronary angiography is consid-
ered the gold standard for assessment of coronary artery stenosis. Even at its best, 
an angiographic image is a two-dimensional profi le of a coronary artery providing 
only indirect information on pathology within the vessel wall. Moreover, reliance on 
coronary angiography as a valid measure of severity and extent of coronary athero-
sclerosis may lead to a lack of accuracy and reproducibility. 
  Although QCA analysis is a major step forward compared to visual analysis of 
the coronary angiograms, currently, the most reliably data on severity and extent of 
CAD would be that obtained by IVUS. Especially in the evaluation of early athero-
sclerotic changes, IVUS is superior to coronary angiography by providing accurate 
images of arterial wall. Limitations of IVUS, on the other hand, include diffi culty 
in imaging small, distal coronary segments, inability to cross severe lesions, and 
suboptimal characterization of plaque components (Topol et al. 1995). Because the 
strengths and limitations of QCA and IVUS, respectively, are largely complemen-
tary, a combination of these two techniques would be optimal in comprehensive 
evaluation of the severity and extent of CAD. 
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  Conventional catheter-driven coronary angiography, while having demonstrated 
effi cacy, also has persistent small but defi nite risks, as a result of its invasiveness and 
requirements for radiation exposure and administration of potentially nephrotoxic 
contrast agent. Thus, the development of a robust, noninvasive test for defi ning 
coronary artery anatomy would be highly desirable.
  Noninvasive electron beam computed tomography (EBCT) has a unique com-
bination of high spatial and temporal resolutions, allowing visualization of small 
lesions. Further, the electrocardiographic triggering allows image acquisition during 
the slow portion of coronary motion. Therefore EBCT appears well suited to cardiac 
imaging. In clinical practice, EBCT has been widely used for detecting and quan-
tifying coronary artery calcifi cations (Budoff et al. 2003). Though coronary artery 
calcifi cation scores correlate well with the total atherosclerotic burden (Agatston et 
al. 1994) and strongly predict future cardiac event (Arad et al. 2000), the amount 
of coronary artery calcifi cation does not correlate well with the stenosis severity of 
a given lesion (Mautner et al. 1994). Three-dimensional contrast-enhanced EBCT-
based angiography has emerged as a technology with the potential for obtaining es-
sentially non-invasive coronary arteriograms. Summary data demonstrate an overall 
sensitivity of 87% and specifi city of 91% for this modality. The main limitations of 
EBCT-based angiography are the relative inability to visualize distal arteries and col-
laterals (Budoff et al. 2003). 
  Coronary magnetic resonance angiography (MRA) is a particularly attractive im-
aging modality without any invasive action or ionizing radiation. The fi rst results 
in 1993 revealed a sensitivity of 90% and a specifi city of 92% for two-dimensional 
coronary MRA as compared with conventional angiography (Manning et al. 1993). 
Despite initial encouraging results and the substantial progress of technical acquisition 
protocols, reported sensitivities and specifi cities in detecting CAD still demonstrate a 
wide variation, and a considerable percentage of segments suffer from degraded image 
quality (Pundziute et al. 2006).
  Multislice computed tomography (MSCT) has emerged as an extremely rapidly 
developing non-invasive cardiac imaging modality. The diagnostic accuracy has been 
signifi cantly improved with the recent development of 64-slice scanners. Available 
data using 64-slice MSCT in comparison with invasive coronary angiography dem-
onstrate sensitivities of 93-99% and specifi cities of 95-97%, making MSCT the most 
promising non-invasive imaging modality for the anatomical evaluation of CAD 
(Pundziute et al. 2006). Still, several important limitations exist. Firstly, the effective 
radiation dose of 64-slice MSCT scanner is substantially higher (14 mSV) than that 
of conventional coronary angiography (6 mSv) (Zanzonico et al. 2006). Secondly, 
although the amount of injected iodinated contrast is decreasing with the newer 
scanner generations, the use of contrast limits examination of patients with impaired 
renal function. Thirdly, despite improved temporal resolution in 64-slice scanners, β 
blockers are still preferable in patients with a heart rate above 70 beats per minutes 
in order to obtain the best results (Pundziute et al. 2006). 
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7.2.2. Ultrasonographic measurement of carotid IMT
Atherosclerosis is viewed as a disorder that is restricted to the intima layer of the ar-
terial vessel wall. So far, an ultrasound image cannot discriminate between the intima 
and media layers of the vessel wall. Thus, an increased IMT may refl ect increases in 
either intima or media thickening, or a combination of both. 
  Different techniques to measure IMT and reproducibility of results have been 
thoroughly reviewed by Kanters et al. (1997). Overall the analogy of the FW IMT 
with histology is more accurate than that of the NW (Wong et al. 1993). Even when 
the NW IMT is well visualized, its measurement is gain-dependent. However, when 
gain settings are standardized, the error is systematic and will not bias associations. 
Moreover, combining NW and FW measurements together seems to reduce the 
variability and thus increase the reliability of results (Kanters et al. 1997).
  The multiple-sites measurements, which were used in our study, usually consist 
of measuring IMT in the near and far walls of the three main segments of extracra-
nial carotid arteries (common carotid artery, carotid bifurcation, and internal carotid 
artery) on both sides. By incorporating measurements of IMT in carotid bifurcation 
and internal carotid artery, early manifestations of carotid atherosclerosis will be 
taken into account. It is well known that atherosclerosis tends to develop in an asym-
metric manner. When the interest is in assessment of atherosclerosis, standardized 
imaging at different angles and at several sites and calculating the common mean 
values from these measurements most likely increase the likelihood of capturing 
all relevant information. More importantly, multiple-sites measurements have given 
results corresponding more closely with CAD than measurements performed at in-
dividual sites (Kanters et al. 1997).
  A pooled analysis and evaluation of prospective trials using IMT measurements 
as surrogate end points of CAD (Bots et al. 2003) recommends the mean of maxi-
mum IMT measurements from several sites at the carotid artery as a primary out-
come measure, and both NW and FW sonographic measurements, to reduce meas-
urement error, increase precision, and estimate the severity and extent of the carotid 
atherosclerosis in a reliable way. Thus, our measurements of IMT are in line with 
the recommendations. 
  Traditionally, the burden of carotid atherosclerosis has been assessed by measure-
ment of IMT. However, ultrasound scanning can be used to measure aspects of ca-
rotid morphology beyond IMT, such as plaque evaluation. In theory, this approach 
has merit; but, in practice, there has not been a clear cut-off point above which an 
atherosclerotic carotid plaque can be defi ned. Recently, the 2004 IMT consensus 
conference (Touboul et al. 2004) defi ned plaque as a focal structure that encroaches 
into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or 
demonstrates a thickness ≥1.5 mm as measured from the media-adventitia interface 
to the intima-lumen interface. Notably, the power of carotid and femoral ultrasound 
scanning results for predicting cardiovascular mortality has been shown to greatly 
increase if presence, number, and thickness of plaques are evaluated together with 
IMT (Griffi n et al. 2002).
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7.3. Carotid atherosclerosis in relation to coronary 
atherosclerosis (Study I)
In accordance with previous quantitative imaging studies (Herrington et al. 1994, 
Blankenhorn et al. 1993), we found that there is a signifi cant relationship between 
ultrasonically determined carotid IMT and coronary atherosclerosis expressed as 
quantitative angiographic indexes of severity, extent, and overall atheroma burden 
of CAD. Herrington et al. (1994), who examined 86 patients with the B-mode 
score (mean of the maximum IMT at 12 sites) and quantitative coronary angiogra-
phy (PDS), found a correlation coeffi cient of r=0.27. Further, in a report from the 
Cholesterol Lowering Atherosclerosis (CLAS) study, Blankenhorn et al. (1993), 
demonstrated that carotid artery IMT is signifi cantly correlated with carotid angi-
ographic vessel edge roughness (r=0.31). 
  There is a signifi cant association between IMT and CAD but, although using re-
fi ned computer-assisted scoring, the correlation coeffi cient remains rather moderate 
suggesting that there are different factors infl uencing on the carotid and coronary 
arteries. It has to be acknowledged that the carotid atherosclerotic process is as in-
dividual as any coronary segment process; thus, the link between IMT and CAD has 
great variation. 
  Epidemiologic data have shown signifi cantly increased cardiovascular event risk 
among those with IMT of 1 mm or greater (Crouse 2001). In agreement, we found 
a sharp increase in CAD severity in subjects with IMTs in quartiles higher than the 
fi rst, corresponding to maximum IMT of 1.16 mm and mean IMT of 0.91 mm or 
more. 
  This study is, to our knowledge, the fi rst to show that associations among maxi-
mum and mean IMT values, respectively, and quantitative angiographic indexes for 
proximal, mid, and distal coronary segments differed. Carotid disease was a weaker 
predictor of CAD in the left main coronary artery and in proximal segments of 
coronary tree than in mid and distal segments. This fi nding is intriguing and against 
conventional wisdom that CAD primarily affects proximal segments, but requires 
further confi rmation.
  The relationship we found in this study supports the hypothesis that increased 
IMT is not only associated with coronary atherosclerotic burden, but that it carries 
independent information as well. As an indicator of cardiovascular disease and pro-
viding a graded measure of vascular damage, carotid IMT may serve as a screening 
test for identifying patients who would benefi t from aggressive diagnostic, therapeu-
tic, and preventive (Greenland et al. 2001) measures. On the other hand, the cor-
relation between carotid IMT and severity and extent of CAD as assessed by QCA is 
too weak to allow utlilization of IMT as a “gatekeeper” for coronary angiography.
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7.4. Determinants of coronary atherosclerosis
7.4.1. PON-1 activity and concentration (Study II)
We detected a signifi cant relationship between PON1 activity and concentration and 
coronary atherosclerosis expressed as quantitative angiographic indexes of severity, 
extent, and overall atheroma burden of CAD. 
  Multiple studies have examined the association between PON1 polymorphisms 
alone and CAD. A recent meta-analysis using all 43 available studies of the PON1 
polymorphisms involving 11 212 CAD cases and 12 786 controls suggested that the 
link between PON1 polymorphism and CAD is at best weak (Wheeler et al. 2004). 
However, the vast majority of the studies have not assessed the quality of PON1, i.e. 
its activity and concentration in the serum. 
  There is, so far, only limited information available about the association between 
directly measured PON1 activity and concentration and angiographically proven 
CAD. Although the difference did not reach statistical signifi cance, Azarsiz et al. 
(2003) found that PON1 activity of patients with CAD (n=68) was lower than 
of patients without CAD (n=33) and controls (n=24). Further, Mackness and co-
workers (2001) showed that PON1 activity and PON1 concentrations were lower 
in subjects with CAD than in control subjects. Notably, the result was independent 
of the PON1 genotype and the authors concluded that the quality of the PON1 
enzyme is a more important factor in CAD than is the PON1 gene. 
  So far, QCA has been applied in only one study comparing PON1 polymor-
phisms and angiographic severity and extent of CAD (Chen et al. 2003a). In a 
report from the Women´s Ischemia Syndrome Evaluation (WISE) study including 
711 women, Chen et al. (2003a) did not fi nd any signifi cant association between the 
PON polymorphisms and stenosis severity in either white or black women. How-
ever, when patients with signifi cant CAD (≥50% stenosis) were stratifi ed into groups 
with one-, two-, or three-vessel CAD, signifi cant associations were noted between 
PON polymorphisms and the number of diseased vessels in whites but not in blacks. 
In contrast to our study, the study of Chen et al. (2003a) comprised only women 
and data on PON1 activity and concentration were not available.
  This study is, to our knowledge, the fi rst to present data on PON1 activity and 
concentration in patients with CAD measured both by visual interpretation and by 
refi ned computer-assisted scoring of coronary angiograms. Our results show that 
PON1 activity and concentration were lower in patients with signifi cant CAD. 
Moreover, PON1 activity and concentration were signifi cantly associated with the 
indexes for global severity, extent, and atheroma burden of CAD. We found a 
stepwise decrease in these QCA-derived indexes across the tertiles of PON1 activ-
ity and concentration. Subjects in the lowest tertile of PON1 activity and concen-
tration, respectively, had a more severe and extensive disease than subjects in the 
highest tertile. 
  Activity and concentration of PON1 can vary up to 40-fold in human popula-
tions (Mueller et al. 1983, Richter et al. 1999). Although PON1 activity and con-
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centration are determined genetically, various kinds of physiological and pathologi-
cal states, such as diet, life-style, environmental chemicals, and drugs can modulate 
PON1 levels. PON1 decreases in older people, during pregnancy, and menopause 
(Mackness et al. 2002). Low serum PON1 activity independent of genotype has 
been reported in diseases associated with accelerated atherogenesis, such as DM, 
hypercholesterolemia, and renal failure (Mackness et al. 1991, Abbott et al. 1995, 
Hasselwander et al. 1998). Degraded cooking oil and an atherogenic diet have 
been reported to lower serum PON1 in humans (Sutherland et al. 1999). Dietary 
polyphenols (present in wine, tea, fruit juice) increase PON1 activity, as does mod-
erate alcohol intake (van der Gaag et al. 1999,  Kaplan et al. 2001). Vitamin C and 
E intake is associated with increased PON1 activity (Jarvik et al. 2002). However, 
another study in which vitamin E was given to volunteers showed no change in 
PON1 activity (Arrol et al. 2000). Smoking is known to decrease serum PON1 
activity (James et al. 2000). Recent evidence shows that exposure to environmental 
chemicals can inhibit PON1 activity (Sozmen et al. 2002, Serhatlioglu et al. 2003). 
Understandably most of the interest in pharmacological effects on PON1 activity 
has, thus far, been in effects of lipid-lowering drugs. Some of these studies (Aviram 
et al. 1998b, Tomas et al. 2000, Paragh et al. 2000), but not all (Durrington et al. 
1998, Turay et al. 2000, Balogh et al. 2001) suggest an effect of statins and fi brates 
in raising PON1 activity. Lately, Hong et al. (2006) demonstrated, in hypercholeste-
rolemic rabbits, that probucol, a cholesterol-lowering drug with antioxidative prop-
erty, increases PON1 serum level as well as mRNA expression of PON1 in hepato-
cytes. Of note, no correlation was observed between PON1 and HDL cholesterol 
level. Additionally, a large case-control study indicated that aspirin users have higher 
serum activities but also concentrations of PON1 (Blatter Garin et al. 2003). Such 
effect may be due to the anti-infl ammatory effect of aspirin, as serum PON1 levels 
are reduced during the infl ammatory response; alternatively, aspirin may act as an 
antioxidant (Blatter Garin et al. 2003).
  In human serum most if not all of the paraoxonase activity is associated with 
HDL. Paraoxonase is present in a distinct HDL subspecies containing apoA-I and 
clusterin or apo J (Blatter et al. 1993). La Du et al. (1989) demonstrated that it is 
extremely diffi cult to remove apoA-I from PON1 during purifi cation from human 
serum, which has led to the suggestion that apoA-I and PON1 are closely associ-
ated. Our results are in line with population studies that have shown a statistical as-
sociation of PON1 activity with HDL cholesterol, apoA-I, and apoA-II (Boman et 
al. 1980, La Du et al. 1989, Abbott et al. 1995).
  Interestingly, our results in the multivariable analyses indicate that PON1 activity 
is a signifi cant determinant of severity of CAD independently of HDL cholesterol, 
apoA-I, and apoA-II. This suggests that PON1 activity has an important role in the 
pathogenesis of coronary atherosclerosis. Our fi ndings demonstrate the relevance of 
PON1 activity and concentration for describing associations between atherosclerotic 
disease and the enzyme. More importantly, the study illustrates how the protective 
role of HDL could be modulated by its components such that equivalent serum 
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concentrations of HDL cholesterol may not equate with an equivalent, potential 
protective capacity. The recent disappointing results with the CETP antagonist 
torcetrapib suggest that not all HDL cholesterol elevating therapy may confer pro-
tection against cardiovascular disease. Additionally, in contrast with other choles-
terol-lowering drugs, probucol is known to decrease HDL cholesterol of around 
20% to 30 %. The clinical signifi cance of this observation is unclear, although some 
investigations suggest a benefi cial effect in enhancing reverse cholesterol transport 
(Sawayama et al. 2002). In fact, probucol has been shown to retard the progression 
of carotid IMT (Sawayama et al. 2002) and to inhibit restenosis after percutaneous 
coronary intervention (Tardif et al. 2003). Nevertheless, clinical use of probucol has 
been limited because of its effects on the QT-interval (Hong et al. 2006). 
  Although signifi cant advances have been made in understanding the PON family 
of proteins, there are still unresolved issues. Firstly, PON1, PON2, and PON3 have 
all shown to protect against LDL oxidation, but their precise physiological function 
remains unknown. Their different enzymatic activities, localization, and regulation 
suggest that they may possess different functions (Ng et al. 2005). Secondly, PON1 
activity can conveniently be directly measured in the serum or plasma. Opinions dif-
fer today, however, which PON1 substrates best represent the “protective” role of 
PON1 in connection with cardiovascular disease. Thirdly, additional information is 
required particularly about nutritional and pharmacological effects on serum PON1 
activity (La Du 2003).
7.4.2. Postprandial lipemia, oxLDL, and LDL particle size 
(Study III)
The present data demonstrate, for the fi rst time in patients with clinically suspected 
CAD referred for coronary angiography, that circulating oxLDL signifi cantly increases 
postprandially. There was a highly signifi cant positive correlation between postpran-
dial TRLs and postprandial oxLDL suggesting that the postprandial state creates oxi-
dative stress. In this cohort, multivariate analysis revealed that postprandial oxLDL in-
dependently predicted the severity and extent of coronary atherosclerosis determined 
by QCA. This emphasizes the pivotal role of LDL oxidation in the development of 
atherosclerosis even after inclusion of conventional CAD risk factors.
  Small, dense LDLs are more susceptible to oxidation than native LDL particles 
(de Graaf et al. 1991, Diwadkar et al. 1999). It has recently been reported that, in a 
cohort of patients with myocardial infarction, the marked accumulation of TRLs ac-
celerated the remodeling of LDL particles toward smaller, denser particles (Koba et 
al. 2005). In contrast to Koba et al. (2005), we did not fi nd any signifi cant changes 
in LDL particle size. Likewise, we have previously reported that LDL particle size 
did not change during an 8-h postprandial period in patients with type 2 DM (Vak-
kilainen et al. 2002b). We found, however, an inverse relation between LDL particle 
size and TRLs postprandially. This is in agreement with the well-established inverse 
correlation of serum TGs with LDL particle size (Packard et al. 2000). 
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  The role of TGs as an independent risk factor of CAD has been debated for dec-
ades. A meta-analysis of 29 prospective population-based studies indicated highly 
signifi cant associations between TG values and CHD risk. However, these associa-
tions depended considerably on levels of established risk factors, especially HDL 
cholesterol (Sarwar et al. 2007). In the Honolulu Heart Study, RLP levels did not 
provide additional information about CHD incidence as compared to concentration 
of total TGs (Imke et al. 2005). They speculated that their result could be attributed 
to the strong correlation between RLP levels and total TGs. Similarly, we found a 
strong correlation between RLP-C and total TGs both in the fasting and in the fed 
state. In the present study TGs, apoB-48, apoB-100, and RLP-C at fasting or at 
postprandial state did not associate with the severity and extent of coronary athero-
sclerosis determined by QCA. In addition, in multivariate analysis neither fasting 
nor postprandial TGs were independent determinants of global atheroma burden 
index. 
  Traditionally TRLs have been isolated by density-gradient ultracentrifugation. 
Due to the fact that this method is complex and time-consuming a new technique 
to isolate remnant lipoproteins was developed using an immunoaffi nity mixed gel 
containing anti-apoA-I and anti-apoB-100 monoclonal antibodies (Nakajima et al. 
1993). We employed a RLP assay to quantify the postprandial increase of TRLs in 
order to gain more information on atherogenicity. The correlations between TGs, 
apoB-48, and apoB-100 in TRLs isolated by density-gradient ultracentrifugation 
and RLPs in fasting and postprandial state were highly signifi cant. Thus, the excel-
lent correlations especially postprandially suggest that the RLP assay is a good sup-
plement to the tedious method of ultracentrifugation. 
  Holvoet and his colleagues (2001) were the fi rst to clearly demonstrate that pa-
tients with angiographically proven CAD had signifi cantly elevated plasma levels of 
oxLDL measured in the fasting state. Recently, Meisinger et al. (2005) concluded, 
in a prospective study comprising men, that oxLDL was a stronger predictor of risk 
than standard lipid variables and other traditional risk factors. We observed a signifi -
cant increase of circulating oxLDL after the fatty meal. Interestingly, postprandial 
oxLDL was a signifi cant predictor of severity and extent of coronary atherosclerosis 
using refi ned computer-assisted scoring of coronary angiograms. Our fi ndings are 
in agreement with data suggesting that oxidative stress is increased postprandially 
(Diwadkar et al. 1999, Ceriello et al. 2004). However, to the best of our knowl-
edge, this has not been previously reported at postprandial state in CAD patients 
rigorously assessed for coronary atherosclerosis by QCA. Furthermore, circulating 
oxLDL and small, dense LDL particles were associated with remnants of TRLs em-
phasizing the atherogenic nature of postprandial state. 
  Lecitin-like oxLDL receptor-1 (LOX-1) is a vascular endothelial receptor for 
ox-LDL (Sawamura et al. 1997). Shin et al. (2004) reported that RLPs caused 
LOX-1 protein expression, and that increased production of both superoxide and 
cytokines and enhanced DNA fragmentation by RLPs was signifi cantly inhibited by 
monoclonal antibody for LOX-1 receptor. They showed that RLPs caused a signifi -
cant increase in nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase-
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dependent superoxide production via activated LOX-1 receptors. These fi ndings 
strongly suggest that LOX-1 is a receptor for RLP as well as oxLDL on endothelial 
cells.
  Although emerging evidence utilizing immunological techniques suggests an im-
pact of circulating oxLDL on CAD, there are some caveats concerning the extent of 
modifi cation and reproducibility of the reference oxLDL preparations that are used as 
standards for these assays. There is only one epitope measured in these assays whereas 
potentially many epitopes may exist on any one individual LDL, and the fact that dif-
ferent populations of oxLDL may exist. The only way to be certain of the amount of 
a particular epitope that is quantitated is to ensure that the reference standard has the 
same extent of oxidation on LDL as the measured LDL. The quantitation of oxLDL 
will be improved when the epitopes are better delineated and the reference standard 
can be a stable pure preparation of the epitope (Tsimikas et al. 2001). 
7.4.3. Insulin resistance (Study IV)
This study indicated that IR was associated with coronary atherosclerosis expressed 
as quantitative angiographic indexes of severity, extent, and overall atheroma burden 
of CAD. In addition, IR seemed to be a stronger predictor of coronary atherosclero-
sis in the distal parts of the coronary tree than in the proximal and mid parts. In the 
multivariate analysis IR was a signifi cant predictor of the severity of CAD. 
  To our knowledge, only two studies have investigated the relationship between 
IR and coronary atherosclerosis utilizing quantitative imaging techniques. Korpilahti 
et al. (1998) showed that, in a 5-year follow-up study of 228 coronary artery bypass 
surgery patients, IR determined as the insulin sensitivity index was associated with 
both progression of pre-operative atherosclerotic lesions and development of new 
lesions. In studying a cohort of 95 non-diabetic Japanese subjects with CAD veri-
fi ed with semi-quantitative coronary angiography, Tsuchihashi et al. (1999) found 
that hyperinsulinemia was an important risk factor for CAD explaining the severity 
of coronary atherosclerosis. 
  Our study confi rms previous positive fi ndings (Bressler et al. 1996, Sasso et al. 
2004, Yanase et al. 2004) and extends them as: 1) our study population included 
men and women; 2) was across a wide array of disease severity, ranging from angi-
ographically normal coronaries to widespread CAD requiring bypass surgery; 3) our 
study comprised CAD patients with normal and abnormal responses to a 75-g oral 
glucose tolerance test; 4) we used refi ned computer-assisted scoring of CAD; and 
5) we found a positive relationship between age- and gender-adjusted severity of IR 
and coronary atherosclerosis. In fact, non-diabetic subjects with more severe degree 
of IR, i.e. HOMA IR score above the upper median level of 1.8, were comparable 
with diabetic subjects in terms of severity and extent of CAD. 
  Consistent with other reports we found that, besides having a more severe and 
extensive CAD, type 2 diabetic patients more frequently had lesions located on dis-
tal arteries than non-diabetic patients (Henry et al. 1997, Thomas et al. 2002). In 
addition, our data show that even non-diabetic subjects with a more severe degree 
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of IR had a more distal type of CAD compared with individuals with a lower degree 
of IR. To the best of our knowledge, this has not been previously published. 
  The process of lesion formation in CAD is complex. Endothelial dysfunction, an 
imbalance between endothelium-derived vasodilative (e.g., nitric oxide) and vaso-
constrictive (e.g., endotelin-1) factors, is regarded as an early pivotal event in athero-
genesis and cardiovascular disease and is closely linked to obesity and IR (Steinberg 
et al. 1996). In addition, obesity, IR, and endothelial dysfunction coexist and they 
can all be identifi ed in individuals with type 2 DM as well as in various groups at risk 
for type 2 DM, such as in individuals with impaired glucose tolerance, family history 
of type 2 DM, hypertension, and dyslipidemia (Caballero 2003). Recently, Prior and 
co-workers (2005) demonstrated that, even in the absence of traditional coronary 
risk factors, the greatest loss in nitric oxide-mediated, endothelium-dependent fl ow 
occurred when IR was the only abnormality, and this seemed to worsen progres-
sively with more severe states of IR. 
  During the development of coronary atherosclerosis compensatory arterial en-
largement preserves the intraluminal space and delays clinically important lumen 
stenosis (Stiel et al. 1989, Glagov et al. 1987). The mechanism for compensatory 
enlargement is thought to be predominantly mediated by the vascular endothelium 
in response to changes in the hemodynamic, shear stress, and humoral changes in 
the vessel lumen (Gibbons et al. 1994). This coronary artery remodeling has been 
shown to be inadequate or negative in diabetic patients (Vavuranakis et al. 1997, 
Kornowski et al. 1998). Arterial remodeling, however, is not a homogeneous proc-
ess within the vessel wall. Interestingly, Nishioka et al. (2001) reported that, despite 
a similar degree of luminal narrowings, the proximal coronary segments showed 
more prominent compensatory enlargement than the distal arterial segments. Re-
cently, Fischer et al. (2005) found that, in families with myocardial infarction, coro-
nary artery stenoses are particularly heritable at proximal localizations, whereas no 
heritability was found for distal disease. In our study the reason for different impact 
of IR on anatomic characteristics of coronary atherosclerosis remains unclear, but 
our results support a regional heterogeneity in remodeling responses. 
7.4.4. ApoE polymorphism (Study V)
We demonstrated for the fi rst time that apoE polymorphism contributes similarly to 
both ultrasonically determined carotid IMT, and coronary atherosclerosis expressed 
as quantitative index of overall atheroma burden of CAD inside the same popula-
tion. Patients with apoE4 phenotype had an increased carotid IMT and a more 
severe and extensive CAD than patients with apoE3 phenotype. These associations 
were independent of age and gender, which are known to infl uence both carotid and 
coronary atherosclerosis. 
  Multiple studies have examined the association between CAD and apoE poly-
morphism. A recent meta-analysis based on 48 published reports (21 clinical and 27 
angiographically confi rmed CAD) fully supports the impact of the ε4 allele as a sig-
nifi cant risk factor for CAD (Song et al. 2004). The analysis identifi ed a signifi cantly 
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increased risk for CAD among carriers of the ε4 allele compared with carriers of the 
ε3 allele. Furthermore, the meta-analysis found little evidence of an association be-
tween the ε2 allele and CAD risk. 
  To our knowledge, only one previous study has examined the association be-
tween the apoE polymorphism and CAD severity based on a computer-assisted 
analysis of coronary angiograms. Our data confi rms and expands the results shown 
by Chen et al. (2003b) who reported a signifi cant relationship between the ε4 allele 
and coronary artery stenosis measured by QCA. However, unlike our cohort that 
included gender main streaming, i.e. both males and females, the study of Chen et 
al. (2003b) comprised only women. 
  Our data show higher apoB concentrations in patients with apoE4 phenotype. 
The association of ε4 allele with increased LDL cholesterol and apoB concentra-
tions is a well-established issue (Davignon et al. 1999, Curtiss et al. 2000). Possible 
explanations to the atherogenicity of the ε4 allele are the high affi nity of apoE4 to 
apoE-binding receptors, thereby leading to increased apoE-mediated cholesterol 
uptake of liver cells. This increase in the hepatic cholesterol pool has the potential to 
down-regulate the LDL receptor, resulting in an accumulation of LDL cholesterol 
and increased risk of atherosclerosis. Further, ε4 allele may be associated with a high 
intestinal cholesterol absorption effi ciency, but studies have yielded confl icting re-
sults (Miettinen et al. 1992, Bergmann et al. 2003).
  The present study indicates that some of the effects of apoE polymorphism on 
carotid and coronary atherosclerosis may be mediated by Lp(a), since the concen-
tration of Lp(a) was signifi cantly higher in the apoE4 group than in the apoE3 
group. In addition, in the multivariate analyses, including Lp(a) in the model almost 
dropped out the independency of apoE polymorphism. Notably, when age, gender, 
and Lp(a) were included without apoE phenotype in the multivariate model, Lp(a) 
remained a signifi cant predictor of carotid IMT. 
  Little is known about the catabolism of Lp(a). Lp(a) binds weakly to the LDL 
receptor, and it is therefore unlikely that the LDL receptor is the major determinant 
of Lp(a) degradation (Armstrong et al. 1990, Kostner 1993). It has been suggested, 
that LDL receptor-related protein, which is a multi-ligand receptor that binds apoE-
containing remnant lipoproteins, is involved in the metabolism of Lp(a) (März et 
al. 1993). 
  Although substantial evidence has accumulated that elevated Lp(a) is an inde-
pendent risk factor for cardiovascular disease (Danesh et al. 2000) several issues limit 
the utility of Lp(a) screening. First, the quantitative contribution of elevated Lp(a) 
to CHD risk beyond the major risk factors is uncertain. Second, Lp(a) levels vary 
widely among different racial groups. They are higher in African Americans than in 
Caucasians, but an increased risk for CHD associated with higher Lp(a) levels in Af-
rican Americans has not been documented (Moliterno et al. 1995). Third, the major 
obstacles to the progress of Lp(a) research have been issues related to the measure-
ment of Lp(a) and the absence of an international standard. Current methods of 
measuring Lp(a) levels include electrophoresis, electroimmunodiffusion, electroim-
munoassay, radioimmunoassay, immunoturbimetric assay, and ELISA (Danesh et al. 
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2000). Finally, serum Lp(a) is relatively resistant to therapeutic lowering. Among 
currently available drugs, only nicotinic acid reduces Lp(a) concentrations, and only 
moderately (Angelin 1997). To date, no clinical trials have shown that lowering 
Lp(a) levels decreases CHD risk (Fruchart et al. 2004). 
  Higher levels of TRLs, derived from VLDLs and CMs, have been linked to an 
increased risk of atherosclerosis (Karpe et al. 2001, McNamara et al. 2001). RLPs 
measured by immunoseparation techniques are often used as a surrogate measure of 
TRLs. Recently, Devlin et al. (2005) demonstrated that high levels of apo(a)/Lp(a) 
in vivo, inhibited hepatic clearance of remnants, leading to high plasma levels of 
RLPs and markedly enhanced atherosclerosis. Whether this function is associated 
more with the ε4 allele than the ε3 allele is an interesting question, since, in our pa-
tients, RLP-C was higher in patients in the apoE4 group than in the apoE3 group. 
Notably, TGs were also higher in apoE4 carriers than in non-carriers, which is in line 
with the results of the meta-analysis by Dallongeville et al. (1992).
  Still, additional mechanisms may link apoE polymorphism with atherosclero-
sis. Some studies have suggested that the association of apoE polymorphism with 
atherosclerosis cannot be totally attributed to variations in total and LDL cholester-
ols (Eichner et al. 1993, Wilson et al. 1994). In mice, physiological levels of apoE 
can induce atherosclerosis regression independently of lowering plasma cholesterol 
levels (Raffai et al. 2005). Another mechanism was recently proposed by Heeren and 
associates (2004) who reported that the recycling of apoE originating from TRLs 
was impaired in apoE4 in comparison to apoE3 in human hepatoma cells resulting 
in decreased cholesterol effl ux. 
  Because of the polymorphic nature of apoE in humans, there are considerable 
limitations in the current use of apoE genotyping as an assessment of vascular risk. 
First, the frequency of the ε4 allele differs in populations being higher in northern 
parts of Europe where CAD is more prevalent (Davignon et al. 1999). Second, the 
frequency of the ε4 allele has been reported to be age- and gender-related, although 
the data are inconsistent (Kolovou et al. 2003). Third, there is evidence of several 
gene-gene interactions involving the apoE locus. For example, plasma TG levels have 
been found to be simultaneously modulated by variations at the lipoprotein lipase 
gene and the apoE gene (Davignon et al. 1999). Fourth, coexistence of lifestyle fac-
tors can modulate the link between apoE and atherosclerosis. Although the results 
are controversial (Boerwinkel et al. 1991, Lefevre et al. 1997), the ε4 allele has been 
associated with increased LDL cholesterol in response to dietary fat (Tikkanen et al. 
1990, Ordovas et al. 1995). The association between HDL cholesterol and physical 
activity may be apoE dependent (Bernstein et al. 2002). In addition, alcohol intake 
and smoking have shown to infl uence the effect of apoE (Corella et al. 2001, Hum-
phries et al. 2001). Finally, apoE polymorphism shows its protagonism in the fi eld of 
pharmacogenetics. In the study by Pedro-Botet et al. (2001), comprising 328 male 
and female volunteers who participated in a multicenter, double-blind clinical trial 
and received 10 mg/day of atorvastatin, men carrying the ε2 allele appeared to be 
more responsive to statin therapy than those carrying the ε4 allele. Notably, this in-
teraction was absent in women. Further, data suggest that apoE polymorphism have 
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a differential effect on lipids and lipoproteins in postmenopausal women treated 
with hormone-replacement therapy, with ε2 allele carriers showing the most benefi -
cial response (Ordovas et al. 2002). Estrogens are known to upregulate hepatic LDL 
receptors, whereas apoE4 induces its downregulation. Therefore, the estrogenic ef-
fect may be counteracted by the presence of apoE4 isoform. Conversely, apoE2 
upregulates the LDL receptor and may work in syngergy with estrogens to reduce 
LDL cholesterol levels (Ordovas et al. 2002). 
7.5. Determinants of carotid atherosclerosis
7.5.1. PON-1 activity and concentration (Study II)
Only a few studies have examined the association betweeen PON1 activity and con-
centration and carotid artery disease. Jarvik et al. (2000) reported in a case-control 
study, that 106 carotid artery disease cases (i.e. >80% internal carotid artery stenosis 
on angiography) had signifi cantly lower levels of paraoxonase and diazoxonase ac-
tivity. In multivariate analysis they found that PON1 Q/R192 and PON1 M/L55 
genotypes or haplotypes did not predict case-control status unless the activity phe-
notype was also included. Campo et al. (2004) showed, in a study comprising 208 
Sicilian subjects with hypercholesterolemia (i.e. total cholesterol >6 mmol/L), that 
there was no signifi cant association between PON1 Q/R192 and PON1 M/L55 
polymorphisms and ultrasonically measured early carotid atherosclerosis. They did 
not fi nd any signifi cant correlation between PON1 activity using phenylacetate or 
paraoxon and carotid IMT. Additionally, Valabhji et al. (2001) found in a case-
control study, that 35 patients with type 1 DM had increased carotid IMT, but the 
PON1 activity using phenylacetate as substrate was similar in diabetic and non-dia-
betic subjects. Likewise, we could not fi nd a signifi cant association between PON1 
activity and concentration and carotid IMT. 
7.5.2. Postprandial lipemia, oxLDL, and LDL particle size 
(Study III)
A limited number of studies have investigated the relationship between remnant 
lipoproteins and carotid atherosclerosis. Karpe et al. (1998) showed, in a study 
comprising 30 healthy normo- and hypertriglyceridemic middle-aged men, that late 
postprandial TG levels were associated with carotid IMT. Further, Boquist et al. 
(1999) found, in a study including 96 healthy 50-year-old men with an apoE3/E3 
genotype, that postprandial triglyceridemia was an independent risk factor for early 
atherosclerosis. Another study conducted in the same cohort showed that, among 
the major fasting plasma lipids and lipoproteins, common carotid artery IMT was 
most strongly correlated with RLP-C (Karpe et al. 2001). 
  To the best of our knowledge, there are no previous studies on postpandial 
lipemia and carotid IMT in males and females with clinically suspected CAD. Our 
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data argue against an important role for postprandial lipemia in the predisposition 
of carotid atherosclerosis. However, one of the main problems of interpreting the 
associations of TGs with atherosclerosis is the biochemical and metabolic heteroge-
neity of TRLs. 
  Data on associations between carotid IMT and circulating oxLDL or autoan-
tibodies against oxLDL have given inconsistent results. Susceptibility of LDL to 
oxidation has been associated to carotid IMT in 30 eastern Finnish men with ac-
celerated 2-year progression of carotid atherosclerosis (Salonen et al. 1992), in a 
study group of 391 clinically healthy 58-year-old men (Hulthe et al. 2002), as well 
as in a prospective, observational study with more than 3 years of follow-up in 326 
clinically healthy men (Wallenfeldt et al. 2004). In contrast, oxLDL was not re-
lated to carotid IMT in a case-control 10-year follow-up study of 91 patients with 
non-insulin-dependent DM (Uusitupa et al. 1996) or in the large population-based 
Bruneck study (Mayr et al. 2006). The differences in the stages of atherosclerosis, 
study designs, and methods of measuring oxLDL may account for these inconsistent 
fi ndings. 
  LDL particle size has been associated with carotid IMT in middle-aged healthy 
subjects (Skoglund-Andersson et al. 1999, Hulthe et al. 2000a). However, LDL 
particle size was not associated with carotid IMT in patients with hypercholestero-
lemia (Hulthe et al. 2000b) or with CAD risk among elderly subjects (Mykkänen et 
al. 1999). Again, the difference in the stage of atherosclerosis and the study design 
may explain why we were not able to fi nd a signifi cant association between LDL 
particle size and carotid IMT. 
7.5.3. Insulin resistance (Study IV)
The association of IR with carotid IMT has been addressed in several studies, but 
the results are inconsistent. Suzuki et al. (1996) and Shinozaki et al. (1997) re-
ported that IR, in non-diabetic subjects, was independently and signifi cantly associ-
ated with carotid IMT. In contrast, Ishizaka and co-workers (2003) showed that, 
in a study population including 738 with normal glucose tolerance, 334 with both 
impaired fasting glucose and impaired glucose tolerance, and 166 diabetic subjects, 
there was no signifi cant association between HOMA IR and carotid IMT in either 
the group as a whole or in patients with normal glucose tolerance. In the present 
study, the results concerning the relationship between HOMA IR and carotid IMT 
did not reach statistical signifi cance.  
7.5.4. ApoE polymorphism (Study V)  
Carotid atherosclerosis is considered a surrogate marker for coronary atherosclero-
sis; thus, measures of IMT by ultrasound provide a quantitative basis for the extent 
of atherosclerosis. The association between the ε4 allele and an increased carotid 
IMT has been observed in several studies (Terry et al. 1996, Cattin et al. 1997, Elo-
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sua et al. 2004), although others have failed to fi nd such an association (Slooter et al. 
2001, Fernandez-Miranda et al. 2004). Most of these studies have been performed 
in subjects without a relevant atherosclerosis risk, but only two (Terry et al. 1996, 
Fernandez-Miranda et al. 2004) in individuals with CAD. Our data are consistent 
with those documented by Terry et al. (1996), who found a signifi cant association 
of apoE polymorphism with carotid IMT.
84
8. SUMMARY AND CONCLUSIONS
The main fi ndings and conclusions of the present study can be summarized as fol-
lows:
1) In this Finnish cohort of patients undergoing elective coronary angiography, 
there was a signifi cant relationship between ultrasonically determined carotid 
IMT and coronary atherosclerosis expressed as quantitative angiographic indexes 
of the severity, extent, and overall atheroma burden of CAD. We found hetero-
geneity in associations between IMT and CAD indexes according to anatomical 
location of CAD. Maximum and mean IMT values, respectively, were correlated 
with quantitative angiographic indexes for mid and distal segments but not with 
the proximal segments of coronary vessels.  
 Our observations show an association between carotid IMT and the severity and 
extent of CAD.
2) The values of PON1 activity and concentration, respectively, were lower in sub-
jects with signifi cant CAD and there was a signifi cant relationship between PON1 
activity and concentration and CAD assessed by QCA. PON1 acitivity was a 
signifi cant determinant of severity of CAD independently of HDL cholesterol, 
apoA-I, and apoA-II. This suggests that PON1 activity has an important role in 
the pathogenesis of coronary atherosclerosis. 
 Our data demonstrate the relevance of PON1 activity and concentration for 
describing associations between atherosclerotic disease and the enzyme. More 
importantly, the study illustrates how the protective role of HDL could be mod-
ulated by its components such that equivalent serum concentrations of HDL 
cholesterol may not equate with an equivalent, potential protective capacity.
3) RLP-C in the fasting state is a good marker of postprandial TRLs. Circulating 
oxLDL increases in CAD patients postprandially. We noticed a highly signifi cant 
positive correlation between postprandial TRLs and postprandial oxLDL, which 
suggests that the postprandial state creates oxidative stress. Postprandial oxLDL 
independently predicted the severity and extent of CAD determined by QCA.
 Our fi ndings emphasize the pivotal role of LDL oxidation in the development of 
atherosclerosis even after inclusion of conventional CAD risk factors. 
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4) IR was associated with an increased severity and extent of coronary atherosclero-
sis and seemed to be a stronger predictor of coronary atherosclerosis in the distal 
parts of the coronary tree than in the proximal and mid parts. In the multivariate 
analysis IR was a signifi cant predictor of the severity of CAD. 
 Our data suggest that disturbances in glucose metabolism play an important role 
in pathogenesis of coronary atherosclerosis. In view of our results, it seems ap-
propriate to intensify efforts to identify insulin-resistant individuals so that inten-
sive treatment strategies can be directed to lower their risk of CAD and to delay 
the onset of type 2 DM.
5) ApoE polymorphism contributes similarly to both ultrasonically determined ca-
rotid IMT and coronary atherosclerosis expressed as quantitative index of overall 
atheroma burden of CAD inside the same population. Patients with the apoE4 
phenotype had an increased carotid IMT and a more severe and extensive CAD 
than patients with the apoE3 phenotype. 
 Our results indicate that apoE polymorphism is involved in the susceptibility to 
both carotid and coronary atherosclerosis. 
Future implications for research:
Our fi ndings highlight the complex relationships between traditional and emerg-
ing cardiovascular risk factors and atherosclerotic disease burden. Indeed, they shed 
some new intriguing light on the complexity. Therefore, it would be interesting to 
confi rm these results in a large population of patients with clinically suspected CAD. 
Moreover, it is highly desirable to increase the clinical understanding of atheroscle-
rotic plaques prone to rupture. The latest technology developed for this purpose 
is spectral analysis of IVUS radio frequency data. This technique has improved the 
in vivo tissue characterization in CAD to a degree that it is called virtual histology 
(VH). 
  In a further study it would be exciting to identify patients at increased risk of 
cardiovascular events incorporated in a multivariate score comprising cardiovascular 
risk factors, data from carotid IMT, coronary angiography, conventional IVUS, and 
VH IVUS. There has never been a simple answer to a complex diagnostic problem. 
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